1
|
Parra Bravo C, Naguib SA, Gan L. Cellular and pathological functions of tau. Nat Rev Mol Cell Biol 2024; 25:845-864. [PMID: 39014245 DOI: 10.1038/s41580-024-00753-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2024] [Indexed: 07/18/2024]
Abstract
Tau protein is involved in various cellular processes, including having a canonical role in binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative diseases marked by the abnormal accumulation of tau protein aggregates in neurons, as seen, for example, in conditions such as frontotemporal dementia and Alzheimer disease. Mutations in tau coding regions or that disrupt tau mRNA splicing, tau post-translational modifications and cellular stress factors (such as oxidative stress and inflammation) increase the tendency of tau to aggregate and interfere with its clearance. Pathological tau is strongly implicated in the progression of neurodegenerative diseases, and the propagation of tau aggregates is associated with disease severity. Recent technological advancements, including cryo-electron microscopy and disease models derived from human induced pluripotent stem cells, have increased our understanding of tau-related pathology in neurodegenerative conditions. Substantial progress has been made in deciphering tau aggregate structures and the molecular mechanisms that underlie protein aggregation and toxicity. In this Review, we discuss recent insights into the diverse cellular functions of tau and the pathology of tau inclusions and explore the potential for therapeutic interventions.
Collapse
Affiliation(s)
- Celeste Parra Bravo
- Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA
- Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
| | - Sarah A Naguib
- Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA
| | - Li Gan
- Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
- Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
| |
Collapse
|
2
|
Zima L, Moore AN, Smolen P, Kobori N, Noble B, Robinson D, Hood KN, Homma R, Al Mamun A, Redell JB, Dash PK. The evolving pathophysiology of TBI and the advantages of temporally-guided combination therapies. Neurochem Int 2024; 180:105874. [PMID: 39366429 DOI: 10.1016/j.neuint.2024.105874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Revised: 09/26/2024] [Accepted: 10/01/2024] [Indexed: 10/06/2024]
Abstract
Several clinical and experimental studies have demonstrated that traumatic brain injury (TBI) activates cascades of biochemical, molecular, structural, and pathological changes in the brain. These changes combine to contribute to the various outcomes observed after TBI. Given the breadth and complexity of changes, combination treatments may be an effective approach for targeting multiple detrimental pathways to yield meaningful improvements. In order to identify targets for therapy development, the temporally evolving pathophysiology of TBI needs to be elucidated in detail at both the cellular and molecular levels, as it has been shown that the mechanisms contributing to cognitive dysfunction change over time. Thus, a combination of individual mechanism-based therapies is likely to be effective when maintained based on the time courses of the cellular and molecular changes being targeted. In this review, we will discuss the temporal changes of some of the key clinical pathologies of human TBI, the underlying cellular and molecular mechanisms, and the results from preclinical and clinical studies aimed at mitigating their consequences. As most of the pathological events that occur after TBI are likely to have subsided in the chronic stage of the disease, combination treatments aimed at attenuating chronic conditions such as cognitive dysfunction may not require the initiation of individual treatments at a specific time. We propose that a combination of acute, subacute, and chronic interventions may be necessary to maximally improve health-related quality of life (HRQoL) for persons who have sustained a TBI.
Collapse
Affiliation(s)
- Laura Zima
- Departments of Neurosurgery, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Anthony N Moore
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Paul Smolen
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Nobuhide Kobori
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Brian Noble
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Dustin Robinson
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Kimberly N Hood
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Ryota Homma
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Amar Al Mamun
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - John B Redell
- Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Pramod K Dash
- Departments of Neurosurgery, The University of Texas McGovern Medical School, Houston, TX, USA; Departments of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, TX, USA.
| |
Collapse
|
3
|
Li L, Nguyen A, Zhao B, Vest R, Yerra L, Sun B, Luo J. Small Molecule Drug C381 Attenuates Brain Vascular Damage Following Repetitive Mild Traumatic Injury. Neurotrauma Rep 2024; 5:1016-1026. [PMID: 39464529 PMCID: PMC11499285 DOI: 10.1089/neur.2024.0060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2024] Open
Abstract
Traumatic brain injury (TBI) remains a significant public health concern, with no effective therapeutic interventions to ameliorate the enduring consequences. The prevailing understanding of TBI pathophysiology indicates a central role for vascular dysfunction. Transforming growth factor-β (TGF-β) is a multifunctional cytokine crucial for vascular development. Aberrant TGF-β signaling is implicated in vascular pathologies associated with various neurological conditions. We recently developed a novel small molecule drug, C381, a TGF-β activator with the ability to restore lysosomal function. Here we used a mouse model of repetitive mild TBI (mTBI) to examine whether C381 would attenuate vascular injury. We first employed RNA-seq analysis to investigate the gene expression patterns associated with mTBI and evaluated the therapeutic potential of C381 in mitigating these changes. Our results demonstrate distinct mTBI-related gene expression signatures, prominently implicating pathways related to vascular integrity and endothelial function. Notably, treatment with C381 reversed these mTBI-induced gene expression changes. Immunohistochemical analysis further corroborated these findings, revealing that C381 treatment attenuated vascular damage in mTBI-affected brain tissue. These findings strongly support the potential clinical usefulness of C381 as a novel therapeutic intervention for mTBI.
Collapse
Affiliation(s)
- Lulin Li
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Andy Nguyen
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Brian Zhao
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Ryan Vest
- Department of Chemical Engineering, Stanford University, Stanford, California, USA
| | - Lakshmi Yerra
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Bryan Sun
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Jian Luo
- Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA
- Polytrauma System of Care, VA Palo Alto Health Care System, Palo Alto, California, USA
| |
Collapse
|
4
|
McAllister TW, Broglio SP, Perkins SM, Katz BP, Pasquina PF, McCrea MA. Characterizing the Effects of Concussion and Head Impact Exposure: Design, Methods, and Participant Traits of the CARE 2.0 Study. J Neuropsychiatry Clin Neurosci 2024:appineuropsych20240022. [PMID: 39385574 DOI: 10.1176/appi.neuropsych.20240022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/12/2024]
Abstract
OBJECTIVE This article describes the design, methods, and participant characteristics of the second phase of the Concussion Assessment, Research, and Education (CARE) Consortium study ("CARE 2.0") of the effects of concussion and repetitive head impact exposure on neuropsychiatric health. METHODS The authors conducted a prospective multisite observational study of male and female collegiate athletes and military service academy cadets and midshipmen participating in the CARE study. Participants were assessed at three time points: undergraduate baseline (UB), before departure from university or service academy (exit), and up to 6 years following graduation (postgrad) via an online battery of brain health assessments. Participant characteristics were compared across the three time points and four levels of head impact exposure. RESULTS A total of 4,643 participants completed the exit assessment, and 3,981 completed the postgrad assessment. Relative to the UB assessment cohort, the exit and postgrad assessment cohorts differed with respect to the percentage of women, baseline Wechsler Test of Adult Reading scores, National Collegiate Athletic Association division category, sport contact level, and number of previous concussions. The median standardized difference across balancing variables, assessment time points, and degree of head impact exposure was 0.12 (with 90% of effect sizes ≤0.29). CONCLUSIONS Although there were some statistically significant differences between participants across assessments, the effect sizes were modest, and overall the data suggest that the exit and postgrad cohorts reflect the characteristics of the baseline cohort. The CARE study design and its large, richly characterized sample provide an opportunity to answer important questions about cumulative and persistent effects of concussion and repetitive head impact exposure on neuropsychiatric health.
Collapse
Affiliation(s)
- Thomas W McAllister
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| | - Steven P Broglio
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| | - Susan M Perkins
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| | - Barry P Katz
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| | - Paul F Pasquina
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| | - Michael A McCrea
- Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea)
| |
Collapse
|
5
|
Arciniega H, Baucom ZH, Tuz-Zahra F, Tripodis Y, John O, Carrington H, Kim N, Knyazhanskaya EE, Jung LB, Breedlove K, Wiegand TLT, Daneshvar DH, Rushmore RJ, Billah T, Pasternak O, Coleman MJ, Adler CH, Bernick C, Balcer LJ, Alosco ML, Koerte IK, Lin AP, Cummings JL, Reiman EM, Stern RA, Shenton ME, Bouix S. Brain morphometry in former American football players: findings from the DIAGNOSE CTE research project. Brain 2024; 147:3596-3610. [PMID: 38533783 PMCID: PMC11449133 DOI: 10.1093/brain/awae098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 02/16/2024] [Accepted: 03/02/2024] [Indexed: 03/28/2024] Open
Abstract
Exposure to repetitive head impacts in contact sports is associated with neurodegenerative disorders including chronic traumatic encephalopathy (CTE), which currently can be diagnosed only at post-mortem. American football players are at higher risk of developing CTE given their exposure to repetitive head impacts. One promising approach for diagnosing CTE in vivo is to explore known neuropathological abnormalities at post-mortem in living individuals using structural MRI. MRI brain morphometry was evaluated in 170 male former American football players ages 45-74 years (n = 114 professional; n = 56 college) and 54 same-age unexposed asymptomatic male controls (n = 54, age range 45-74). Cortical thickness and volume of regions of interest were selected based on established CTE pathology findings and were assessed using FreeSurfer. Group differences and interactions with age and exposure factors were evaluated using a generalized least squares model. A separate logistic regression and independent multinomial model were performed to predict each traumatic encephalopathy syndrome (TES) diagnosis, core clinical features and provisional level of certainty for CTE pathology using brain regions of interest. Former college and professional American football players (combined) showed significant cortical thickness and/or volume reductions compared to unexposed asymptomatic controls in the hippocampus, amygdala, entorhinal cortex, parahippocampal gyrus, insula, temporal pole and superior frontal gyrus. Post hoc analyses identified group-level differences between former professional players and unexposed asymptomatic controls in the hippocampus, amygdala, entorhinal cortex, parahippocampal gyrus, insula and superior frontal gyrus. Former college players showed significant volume reductions in the hippocampus, amygdala and superior frontal gyrus compared to the unexposed asymptomatic controls. We did not observe Age × Group interactions for brain morphometric measures. Interactions between morphometry and exposure measures were limited to a single significant positive association between the age of first exposure to organized tackle football and right insular volume. We found no significant relationship between brain morphometric measures and the TES diagnosis core clinical features and provisional level of certainty for CTE pathology outcomes. These findings suggested that MRI morphometrics detect abnormalities in individuals with a history of repetitive head impact exposure that resemble the anatomic distribution of pathological findings from post-mortem CTE studies. The lack of findings associating MRI measures with exposure metrics (except for one significant relationship) or TES diagnosis and core clinical features suggested that brain morphometry must be complemented by other types of measures to characterize individuals with repetitive head impacts.
Collapse
Affiliation(s)
- Hector Arciniega
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- Department of Rehabilitation Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA
- NYU Concussion Center, NYU Langone Health, New York, NY 10016, USA
| | - Zachary H Baucom
- Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
| | - Fatima Tuz-Zahra
- Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
| | - Yorghos Tripodis
- Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
| | - Omar John
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- Department of Rehabilitation Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA
- NYU Concussion Center, NYU Langone Health, New York, NY 10016, USA
| | - Holly Carrington
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
| | - Nicholas Kim
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
| | - Evdokiya E Knyazhanskaya
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
| | - Leonard B Jung
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- cBRAIN, Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy, University Hospital Ludwig-Maximilians-Universität, Munich, Bavaria 80336, Germany
| | - Katherine Breedlove
- Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Tim L T Wiegand
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- cBRAIN, Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy, University Hospital Ludwig-Maximilians-Universität, Munich, Bavaria 80336, Germany
| | - Daniel H Daneshvar
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA 02115, USA
- Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA 02129, USA
| | - R Jarrett Rushmore
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- Department of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
| | - Tashrif Billah
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
| | - Ofer Pasternak
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Michael J Coleman
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
| | - Charles H Adler
- Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
| | - Charles Bernick
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA
- Department of Neurology, University of Washington, Seattle, WA 98195, USA
| | - Laura J Balcer
- Department of Neurology, NYU Grossman School of Medicine, New York, NY 10017, USA
- Department of Population Health, NYU Grossman School of Medicine, New York, NY 10017, USA
- Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY 10017, USA
| | - Michael L Alosco
- Department of Neurology, Boston University Alzheimer’s Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
| | - Inga K Koerte
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- cBRAIN, Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy, University Hospital Ludwig-Maximilians-Universität, Munich, Bavaria 80336, Germany
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
- Graduate School of Systemic Neurosciences, Ludwig-Maximilians-Universität, 82152 Munich, Bavaria, Germany
| | - Alexander P Lin
- Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Jeffrey L Cummings
- Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV 89154, USA
| | - Eric M Reiman
- Banner Alzheimer’s Institute and Arizona Alzheimer’s Consortium, Phoenix, AZ 85006, USA
- Department of Psychiatry, University of Arizona, Phoenix, AZ 85004, USA
- Department of Psychiatry, Arizona State University, Phoenix, AZ 85008, USA
- Neurogenomics Division, Translational Genomics Research Institute and Alzheimer’s Consortium, Phoenix, AZ 85004, USA
| | - Robert A Stern
- Department of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
- Department of Neurology, Boston University Alzheimer’s Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
- Department of Neurosurgery, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
| | - Martha E Shenton
- Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02145, USA
- Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Sylvain Bouix
- Department of Software Engineering and Information Technology, École de technologie supérieure, Université du Québec, Montréal, QC H3C 1K3, Canada
| |
Collapse
|
6
|
Arciniega H, Jung LB, Tuz-Zahra F, Tripodis Y, John O, Kim N, Carrington HW, Knyazhanskaya EE, Chamaria A, Breedlove K, Wiegand TL, Daneshvar D, Billah T, Pasternak O, Coleman MJ, Adler CH, Bernick C, Balcer LJ, Alosco ML, Lin AP, Koerte IK, Cummings JL, Reiman EM, Stern RA, Bouix S, Shenton ME. Cavum Septum Pellucidum in Former American Football Players: Findings From the DIAGNOSE CTE Research Project. Neurol Clin Pract 2024; 14:e200324. [PMID: 39161749 PMCID: PMC11332980 DOI: 10.1212/cpj.0000000000200324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Accepted: 04/02/2024] [Indexed: 08/21/2024]
Abstract
Background and Objectives Exposure to repetitive head impacts (RHI) is linked to the development of chronic traumatic encephalopathy (CTE), which can only be diagnosed at post-mortem. The presence of a cavum septum pellucidum (CSP) is a common finding in post-mortem studies of confirmed CTE and in neuroimaging studies of individuals exposed to RHI. This study examines CSP in living former American football players, investigating its association with RHI exposure, traumatic encephalopathy syndrome (TES) diagnosis, and provisional levels of certainty for CTE pathology. Methods Data from the DIAGNOSE CTE Research Project were used to compare the presence and ratio of CSP in former American football players (n = 175), consisting of former college (n = 58) and former professional players (n = 117), and asymptomatic unexposed controls without RHI exposure (n = 55). We further evaluated potential associations between CSP measures and cumulative head impact index (CHII) measures (frequency, linear acceleration, and rotational force), a TES diagnosis (yes/no), and a provisional level of certainty for CTE pathology (suggestive, possible, and probable). Results Former American football players exhibited a higher CSP presence and ratio than unexposed asymptomatic controls. Among player subgroups, professional players showed a greater CSP ratio than former college players and unexposed asymptomatic controls. Among all football players, CHII rotational forces correlated with an increased CSP ratio. No significant associations were found between CSP measures and diagnosis of TES or provisional levels of certainty for CTE pathology. Discussion This study confirms previous findings, highlighting a greater prevalence of CSP and a greater CSP ratio in former American football players compared with unexposed asymptomatic controls. In addition, former professional players showed a greater CSP ratio than college players. Moreover, the relationship between estimates of CHII rotational forces and CSP measures suggests that cumulative frequency and strength of rotational forces experienced in football are associated with CSP. However, CSP does not directly correlate with TES diagnosis or provisional levels of certainty for CTE, indicating that it may be a consequence of RHI associated with rotational forces. Further research, especially longitudinal studies, is needed for confirmation and to explore changes over time.
Collapse
Affiliation(s)
- Hector Arciniega
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Leonard B Jung
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Fatima Tuz-Zahra
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Yorghos Tripodis
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Omar John
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Nicholas Kim
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Holly W Carrington
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Evdokiya E Knyazhanskaya
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Arushi Chamaria
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Katherine Breedlove
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Tim L Wiegand
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Daniel Daneshvar
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Tashrif Billah
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Ofer Pasternak
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Michael J Coleman
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Charles H Adler
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Charles Bernick
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Laura J Balcer
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Michael L Alosco
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Alexander P Lin
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Inga K Koerte
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Jeffrey L Cummings
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Eric M Reiman
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Robert A Stern
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Sylvain Bouix
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Martha E Shenton
- Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada
| |
Collapse
|
7
|
Giesler LP, Mychasiuk R, Shultz SR, McDonald SJ. BDNF: New Views of an Old Player in Traumatic Brain Injury. Neuroscientist 2024; 30:560-573. [PMID: 37067029 PMCID: PMC11423547 DOI: 10.1177/10738584231164918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/18/2023]
Abstract
Traumatic brain injury is a common health problem affecting millions of people each year. BDNF has been investigated in the context of traumatic brain injury due to its crucial role in maintaining brain homeostasis. Val66Met is a functional single-nucleotide polymorphism that results in a valine-to-methionine amino acid substitution at codon 66 in the BDNF prodomain, which ultimately reduces secretion of BDNF. Here, we review experimental animal models as well as clinical studies investigating the role of the Val66Met single-nucleotide polymorphism in traumatic brain injury outcomes, including cognitive function, motor function, neuropsychiatric symptoms, and nociception. We also review studies investigating the role of BDNF on traumatic brain injury pathophysiology as well as circulating BDNF as a biomarker of traumatic brain injury.
Collapse
Affiliation(s)
| | - Richelle Mychasiuk
- Department of Neuroscience, Monash University, Melbourne, Australia
- Department of Neurology, The Alfred Hospital, Melbourne, Australia
| | - Sandy R. Shultz
- Department of Neuroscience, Monash University, Melbourne, Australia
- Department of Neurology, The Alfred Hospital, Melbourne, Australia
| | - Stuart J. McDonald
- Department of Neuroscience, Monash University, Melbourne, Australia
- Department of Neurology, The Alfred Hospital, Melbourne, Australia
| |
Collapse
|
8
|
Conway Kleven B, Chien LC, Young DL, Cross CL, Labus B, Bernick C. Repetitive head impacts among professional fighters: a pilot study evaluating Traumatic Encephalopathy Syndrome and postural balance. PHYSICIAN SPORTSMED 2024; 52:513-519. [PMID: 38418380 DOI: 10.1080/00913847.2024.2325331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 02/27/2024] [Indexed: 03/01/2024]
Abstract
OBJECTIVES Clinical criteria for Traumatic Encephalopathy Syndrome (ccTES) were developed for research purposes to reflect the clinical symptoms of Chronic Traumatic Encephalopathy (CTE). The aims of this study were to 1) determine whether there was an association between the research diagnosis of TES and impaired postural balance among retired professional fighters, and 2) determine repetitive head impacts (RHI) exposure thresholds among both TES positive and TES negative groups in retired professional fighters when evaluating for balance impairment. METHODS This was a pilot study evaluating postural balance among participants of the Professional Athletes Brain Health Study (PABHS). Among the cohort, 57 retired professional fighters met the criteria for inclusion in this study. A generalized linear model with generalized estimating equations was used to compare various balance measures longitudinally between fighters with and without TES. RESULTS A significant association was observed between a TES diagnosis and worsening performance on double-leg balance assessments when stratifying by RHI exposure thresholds. Additionally, elevated exposure to RHI was significantly associated with increased odds of developing TES; The odds for TES diagnosis were 563% (95% CI = 113, 1963; p-value = 0.0011) greater among athletes with 32 or more professional fights compared to athletes with less than 32 fights when stratifying by balance measures. Likewise, the odds for TES diagnosis were 43% (95% CI = 10, 102; p-value = 0.0439) greater with worsening double leg stance balance in athletes exposed to 32 or more fights. CONCLUSION This pilot study provides preliminary evidence of a relationship between declining postural balance and a TES diagnosis among retired professional fighters with elevated RHI exposure. Further research exploring more complex assessments such as the Functional Gait Assessment may be of benefit to improve clinical understanding of the relationship between TES, RHI, and balance.
Collapse
Affiliation(s)
- Brooke Conway Kleven
- Sports Innovation Institute, University of Nevada, Las Vegas, Las Vegas, NV, USA
- School of Public Health, Department of Epidemiology and Biostatistics, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Lung-Chang Chien
- School of Public Health, Department of Epidemiology and Biostatistics, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Daniel L Young
- School of Integrated Health Sciences, Department of Physical Therapy, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Chad L Cross
- School of Public Health, Department of Epidemiology and Biostatistics, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Brian Labus
- School of Public Health, Department of Epidemiology and Biostatistics, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Charles Bernick
- Department of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
| |
Collapse
|
9
|
Harej Hrkać A, Pilipović K, Belančić A, Juretić L, Vitezić D, Mršić-Pelčić J. The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury. Pharmaceuticals (Basel) 2024; 17:1313. [PMID: 39458954 PMCID: PMC11510130 DOI: 10.3390/ph17101313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 09/23/2024] [Accepted: 09/26/2024] [Indexed: 10/28/2024] Open
Abstract
Traumatic brain injury (TBI), which is a global public health concern, can take various forms, from mild concussions to blast injuries, and each damage type has a particular mechanism of progression. However, TBI is a condition with complex pathophysiology and heterogenous clinical presentation, which makes it difficult to model for in vitro and in vivo studies and obtain relevant results that can easily be translated to the clinical setting. Accordingly, the pharmacological options for TBI management are still scarce. Since a wide spectrum of processes, such as glucose homeostasis, food intake, body temperature regulation, stress response, neuroprotection, and memory, were demonstrated to be modulated after delivering glucagon-like peptide 1 (GLP-1) or GLP-1 receptor agonists into the brain, we aimed to speculate on their potential role in TBI management by comprehensively overviewing the preclinical and clinical body of evidence. Based on promising preclinical data, GLP-1 receptor agonists hold the potential to extend beyond metabolic disorders and address unmet needs in neuroprotection and recovery after TBI, but also other types of central nervous system injuries such as the spinal cord injury or cerebral ischemia. This overview can lay the basis for tailoring new research hypotheses for future in vitro and in vivo models in TBI settings. However, large-scale clinical trials are crucial to confirm their safety and efficacy in these new therapeutic applications.
Collapse
Affiliation(s)
- Anja Harej Hrkać
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
| | - Kristina Pilipović
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
| | - Andrej Belančić
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
- Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia
| | - Lea Juretić
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
| | - Dinko Vitezić
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
- Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia
| | - Jasenka Mršić-Pelčić
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; (A.H.H.); (A.B.); (L.J.); (D.V.); (J.M.-P.)
| |
Collapse
|
10
|
Markicevic M, Mandino F, Toyonaga T, Cai Z, Fesharaki-Zadeh A, Shen X, Strittmatter SM, Lake EMR. Repetitive Mild Closed-Head Injury Induced Synapse Loss and Increased Local BOLD-fMRI Signal Homogeneity. J Neurotrauma 2024. [PMID: 39096127 DOI: 10.1089/neu.2024.0095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/04/2024] Open
Abstract
Repeated mild head injuries due to sports, or domestic violence and military service are increasingly linked to debilitating symptoms in the long term. Although symptoms may take decades to manifest, potentially treatable neurobiological alterations must begin shortly after injury. Better means to diagnose and treat traumatic brain injuries requires an improved understanding of the mechanisms underlying progression and means through which they can be measured. Here, we employ a repetitive mild traumatic brain injury (rmTBI) and chronic variable stress mouse model to investigate emergent structural and functional brain abnormalities. Brain imaging is achieved with [18F]SynVesT-1 positron emission tomography, with the synaptic vesicle glycoprotein 2A ligand marking synapse density and BOLD (blood-oxygen-level-dependent) functional magnetic resonance imaging (fMRI). Animals were scanned six weeks after concluding rmTBI/Stress procedures. Injured mice showed widespread decreases in synaptic density coupled with an increase in local BOLD-fMRI synchrony detected as regional homogeneity. Injury-affected regions with higher synapse density showed a greater increase in fMRI regional homogeneity. Taken together, these observations may reflect compensatory mechanisms following injury. Multimodal studies are needed to provide deeper insights into these observations.
Collapse
Affiliation(s)
- Marija Markicevic
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Francesca Mandino
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Takuya Toyonaga
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Zhengxin Cai
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Arman Fesharaki-Zadeh
- Department of Neurology, School of Medicine, Yale University, New Haven, Connecticut, USA
- Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Xilin Shen
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
| | - Stephen M Strittmatter
- Department of Neurology, School of Medicine, Yale University, New Haven, Connecticut, USA
- Department of Neuroscience, School of Medicine, Yale University, New Haven, Connecticut, USA
- Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA
| | - Evelyn M R Lake
- Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, Connecticut, USA
- Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA
| |
Collapse
|
11
|
Silverstein SM. The Potential Utility of Retinal Biomarkers to Index Central Nervous System Effects of Repetitive Blast Exposure in Military Personnel. Mil Med 2024:usae443. [PMID: 39292534 DOI: 10.1093/milmed/usae443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Revised: 08/28/2024] [Accepted: 09/02/2024] [Indexed: 09/20/2024] Open
Abstract
Military personnel exposed to blasts receive repeated subconcussive head impacts. Although these events typically do not cause immediate symptoms and do not lead to medical evaluation, the cumulative effects of subconcussive impacts can be significant and can include postconcussive symptoms, changes in brain structure and function, long-term cognitive dysfunction, depression, and chronic traumatic encephalopathy. Retinal measures such as thickness of retinal neural layers, density of retinal microvasculature, and strength of retinal neuronal firing are associated with cognitive function and brain structure and function in healthy populations and in neurodegenerative disease cohorts, and changes over time in retinal indices predict cognitive decline and brain atrophy in longitudinal studies in a range of medical populations. This commentary highlights the potential benefits of using retinal biomarkers in the routine screening and monitoring of brain health in warfighters and veterans. Retinal measures can be rapidly acquired (often in a matter of seconds) using methods that are inexpensive and noninvasive, and they can be collected with movable and often portable equipment that uses automated scoring routines that can be used for prediction and decision-making at the individual level. To date, however, retinal biomarkers have not been included in studies of blast overpressure exposures in military personnel. Despite this, preclinical and human evidence suggests that they could be among the most effective methods for tracking central nervous system damage in people exposed to repeated blasts. Retinal biomarkers could also contribute to brief test batteries to determine who is most at risk for long-term negative effects of future exposures. In addition, the sensitivity of retinal indices to blast exposure and mild traumatic brain injury suggests that they should be incorporated into research on strategies to minimize or prevent blast-related short- and long-term central nervous system changes in blast-exposed military personnel.
Collapse
Affiliation(s)
- Steven M Silverstein
- Departments of Psychiatry, Neuroscience, and Ophthalmology, University of Rochester Medical Center , Rochester, NY 14642, USA
| |
Collapse
|
12
|
Ferrazzoli D, Ortelli P, Versace V, Stolz J, Dezi S, Vos P, Giladi N, Saltuari L, Sebastianelli L. Post-traumatic parkinsonism: The intricate twist between trauma, inflammation and neurodegeneration. A narrative review. J Neurol Sci 2024; 466:123242. [PMID: 39303348 DOI: 10.1016/j.jns.2024.123242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Revised: 09/10/2024] [Accepted: 09/15/2024] [Indexed: 09/22/2024]
Abstract
Post-traumatic Parkinsonism (PTP) is a complex neurological disorder that is often associated with the occurrence of a traumatic brain injury (TBI). PTP can occur either in the acute or chronic phase of TBI. There is still uncertainty about the mechanisms provoking PTP, which can be the result of the acute blast itself or secondary neurodegenerative process occurring months to years post the acute trauma. Currently there is an underestimation of the clinical importance of PTP and lack of specific and proven therapeutic interventions, both in the pharmacological and the neurorehabilitation field. This narrative review aims to summarize the actual knowledge about PTP in terms of its pathophysiology, clinical aspects, treatments and perspective of care in the neurorehabilitative setting.
Collapse
Affiliation(s)
- Davide Ferrazzoli
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy.
| | - Paola Ortelli
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy
| | - Viviana Versace
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy; Department of Neurology, Neurocritical Care and Neurorehabilitation, Christian Doppler University Hospital, Centre for Cognitive Neuroscience, Paracelsus Medical University (PMU), Salzburg, Austria
| | - Jakob Stolz
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy
| | - Sabrina Dezi
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy
| | - Pieter Vos
- Department of Neurology, Slingeland Hospital, Doetinchem, the Netherlands
| | - Nir Giladi
- Center for the Study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; Department of Neurology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Leopold Saltuari
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy
| | - Luca Sebastianelli
- Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Vipiteno-Sterzing, Italy
| |
Collapse
|
13
|
Alkaslasi MR, Lloyd EYH, Gable AS, Silberberg H, Yarur HE, Tsai VS, Sohn M, Margolin G, Tejeda HA, Le Pichon CE. The transcriptional response of cortical neurons to concussion reveals divergent fates after injury. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.02.26.581939. [PMID: 38463961 PMCID: PMC10925231 DOI: 10.1101/2024.02.26.581939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Traumatic brain injury (TBI) is a risk factor for neurodegeneration, however little is known about how different neuron types respond to this kind of injury. In this study, we follow neuronal populations over several months after a single mild TBI (mTBI) to assess long ranging consequences of injury at the level of single, transcriptionally defined neuronal classes. We find that the stress responsive Activating Transcription Factor 3 (ATF3) defines a population of cortical neurons after mTBI. We show that neurons that activate ATF3 upregulate stress-related genes while repressing many genes, including commonly used markers for these cell types. Using an inducible reporter linked to ATF3, we genetically mark damaged cells to track them over time. Notably, we find that a population in layer V undergoes cell death acutely after injury, while another in layer II/III survives long term and retains the ability to fire action potentials. To investigate the mechanism controlling layer V neuron death, we genetically silenced candidate stress response pathways. We found that the axon injury responsive kinase MAP3K12, also known as dual leucine zipper kinase (DLK), is required for the layer V neuron death. This work provides a rationale for targeting the DLK signaling pathway as a therapeutic intervention for traumatic brain injury. Beyond this, our novel approach to track neurons after a mild, subclinical injury can inform our understanding of neuronal susceptibility to repeated impacts.
Collapse
Affiliation(s)
- Mor R. Alkaslasi
- Unit on the Development of Neurodegeneration, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
- Department of Neuroscience, Brown University, Providence, RI, USA
| | - Eliza Y. H. Lloyd
- Unit on the Development of Neurodegeneration, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Austin S. Gable
- Unit on the Development of Neurodegeneration, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Hanna Silberberg
- Unit on the Development of Neurodegeneration, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Hector E. Yarur
- Unit on Neuromodulation and Synaptic Integration, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
| | - Valerie S. Tsai
- Unit on Neuromodulation and Synaptic Integration, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
| | - Mira Sohn
- Bioinformatics and Scientific Programming Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Gennady Margolin
- Bioinformatics and Scientific Programming Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Hugo A. Tejeda
- Unit on Neuromodulation and Synaptic Integration, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
| | - Claire E. Le Pichon
- Unit on the Development of Neurodegeneration, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
14
|
Fortington LV, Cassidy JD, Castellani RJ, Gardner AJ, McIntosh AS, Austen M, Kerr ZY, Quarrie KL. Epidemiological Principles in Claims of Causality: An Enquiry into Repetitive Head Impacts (RHI) and Chronic Traumatic Encephalopathy (CTE). Sports Med 2024:10.1007/s40279-024-02102-4. [PMID: 39277838 DOI: 10.1007/s40279-024-02102-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2024] [Indexed: 09/17/2024]
Abstract
Determining whether repetitive head impacts (RHI) cause the development of chronic traumatic encephalopathy (CTE)-neuropathological change (NC) and whether pathological changes cause clinical syndromes are topics of considerable interest to the global sports medicine community. In 2022, an article was published that used the Bradford Hill criteria to evaluate the claim that RHI cause CTE. The publication garnered international media attention and has since been promoted as definitive proof that causality has been established. Our counterpoint presents an appraisal of the published article in terms of the claims made and the scientific literature used in developing those claims. We conclude that the evidence provided does not justify the causal claims. We discuss how causes are conceptualised in modern epidemiology and highlight shortcomings in the current definitions and measurement of exposures (RHI) and outcomes (CTE). We address the Bradford Hill arguments that are used as evidence in the original review and conclude that assertions of causality having been established are premature. Members of the scientific community must be cautious of making causal claims until the proposed exposures and outcomes are well defined and consistently measured, and findings from appropriately designed studies have been published. Evaluating and reflecting on the quality of research is a crucial step in providing accurate evidence-based information to the public.
Collapse
Affiliation(s)
- Lauren V Fortington
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
| | - J David Cassidy
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
| | - Rudolph J Castellani
- Division of Neuropathology, Northwestern University Feinberg School of Medicine and Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Chicago, IL, USA
| | - Andrew J Gardner
- Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
| | - Andrew S McIntosh
- Monash University Accident Research Centre, Monash University, Clayton, VIC, Australia
| | - Michael Austen
- Australasian Faculty of Occupational and Environmental Medicine, Royal Australasian College of Physicians, Sydney, Australia
- Royal New Zealand College of Urgent Care, Auckland, New Zealand
- High Court of New Zealand, Auckland, New Zealand
| | - Zachary Yukio Kerr
- Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Kenneth L Quarrie
- New Zealand Rugby, 100 Molesworth Street, Wellington, New Zealand
- Sports Performance Research Institute New Zealand (SPRINZ), Auckland University of Technology, Auckland, New Zealand
- Auckland Bioengineering Institute (ABI), The University of Auckland, Auckland, Auckland, New Zealand
| |
Collapse
|
15
|
Majeed A, Naz N, Namal F, Tahir S, Karmani VK. Chronic Traumatic Encephalopathy: A Comprehensive Narrative Review of Its Biomarkers. Cureus 2024; 16:e69510. [PMID: 39421082 PMCID: PMC11485022 DOI: 10.7759/cureus.69510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/16/2024] [Indexed: 10/19/2024] Open
Abstract
Chronic traumatic encephalopathy (CTE) is a progressive and fatal neurological disorder linked to repeated traumatic brain injuries (TBIs), including concussions and blows to the head. This condition is characterized by the accumulation of abnormally structured hyperphosphorylated tau proteins (p-tau), forming neurofibrillary tangles, astrocytic tangles, and neurites in the brain. CTE is often diagnosed post-mortem, making it challenging to diagnose and predict its progression in living individuals. Despite recent advancements, no definitive pathological, radiological, or neurobiological marker consistently shows promise in diagnosing and predicting the disease. This review aims to summarize the available techniques and advancements in imaging-based, genetic, neuropsychological, and fluid biomarkers for CTE, evaluating their specificity and sensitivity. It will also highlight the limitations of each marker in diagnosing CTE and provide future research directions to enhance the accuracy of CTE diagnosis in living individuals.
Collapse
Affiliation(s)
- Aleena Majeed
- Internal Medicine, Fatima Jinnah Medical University, Lahore, PAK
| | - Nageen Naz
- Internal Medicine, Fatima Jinnah Medical University, Lahore, PAK
| | - Fnu Namal
- Internal Medicine, Social Security Hospital, Faisalabad, PAK
| | - Sohaira Tahir
- Internal Medicine, Avicenna Medical College, Lahore, PAK
| | | |
Collapse
|
16
|
Adams JW, Kirsch D, Calderazzo SM, Tuz-Zahra F, Tripodis Y, Mez J, Alosco ML, Alvarez VE, Huber BR, Kubilus C, Cormier KA, Nicks R, Uretsky M, Nair E, Kuzyk E, Aytan N, Cherry JD, Crary JF, Daneshvar DH, Nowinski CJ, Goldstein LE, Dwyer B, Katz DI, Cantu RC, Stern RA, McKee AC, Stein TD. Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy. JAMA Neurol 2024; 81:916-924. [PMID: 39008284 PMCID: PMC11250391 DOI: 10.1001/jamaneurol.2024.2166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 04/21/2024] [Indexed: 07/16/2024]
Abstract
Importance Parkinsonism is associated with traumatic brain injury and chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with repetitive head impact (RHI) exposure, but the neuropathologic substrates that underlie parkinsonism in individuals with CTE are yet to be defined. Objective To evaluate the frequency of parkinsonism in individuals with CTE and the association of RHI and neuropathologic substrates with parkinsonism in these individuals. Design, Setting, and Participants This cross-sectional study included brain donors with neuropathologically diagnosed CTE without other significant neurodegenerative disease and with information on parkinsonism from the Understanding Neurologic Injury and Traumatic Encephalopathy brain bank between July 2015 and May 2022. Exposure Years of contact sports participation as a proxy for RHI. Main Outcomes and Measures The main outcomes were frequency of parkinsonism in individuals with CTE and associations between (1) RHI with substantia nigra (SN) Lewy bodies (LBs) and neurofibrillary tangles (NFTs); (2) LBs, NFTs, and arteriolosclerosis with SN neuronal loss; and (3) SN neuronal loss, LBs, NFTs, and arteriolosclerosis with parkinsonism, tested by age-adjusted logistic regressions. Results Of 481 male brain donors with neuropathologically diagnosed CTE, parkinsonism occurred frequently in individuals with CTE (119 [24.7%]; 362 [75.3%] did not have parkinsonism). Participants with parkinsonism had a higher mean (SD) age at death (71.5 [13.0] years) than participants without parkinsonism (54.1 [19.3] years) (P < .001) and higher rates of dementia (104 [87.4%] vs 105 [29.0%]), visual hallucinations (45 [37.8%] vs 51 [14.1%]), and probable rapid eye movement sleep behavior disorder (52 [43.7%] vs 58 [16.0%]) (P < .001 for all). Participants with parkinsonism had a more severe CTE stage (eg, stage IV: 35 [29.4%] vs 39 [10.8%]) and nigral pathology than those without parkinsonism (NFTs: 50 of 117 [42.7%] vs 103 of 344 [29.9%]; P = .01; neuronal loss: 61 of 117 [52.1%] vs 59 of 344 [17.1%]; P < .001; and LBs: 28 of 116 [24.1%] vs 20 of 342 [5.8%]; P < .001). Years of contact sports participation were associated with SN NFTs (adjusted odds ratio [AOR], 1.04; 95% CI, 1.00-1.07; P = .03) and neuronal loss (AOR, 1.05; 95% CI, 1.01-1.08; P = .02). Nigral neuronal loss (AOR, 2.61; 95% CI, 1.52-4.47; P < .001) and LBs (AOR, 2.29; 95% CI, 1.15-4.57; P = .02) were associated with parkinsonism. However, SN neuronal loss was associated with SN LBs (AOR, 4.48; 95% CI, 2.25-8.92; P < .001), SN NFTs (AOR, 2.51; 95% CI, 1.52-4.15; P < .001), and arteriolosclerosis (AOR, 2.27; 95% CI, 1.33-3.85; P = .002). In American football players, regression analysis demonstrated that SN NFTs and neuronal loss mediated the association between years of play and parkinsonism in the context of CTE (β, 0.012; 95% CI, 0.001-0.038). Conclusions and Relevance In this cross-sectional study of contact sports athletes with CTE, years of contact sports participation were associated with SN tau pathology and neuronal loss, and these pathologies were associated with parkinsonism. Repetitive head impacts may incite neuropathologic processes that lead to symptoms of parkinsonism in individuals with CTE.
Collapse
Affiliation(s)
- Jason W. Adams
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurosciences, University of California, San Diego School of Medicine, La Jolla
| | - Daniel Kirsch
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Samantha M. Calderazzo
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Fatima Tuz-Zahra
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Yorghos Tripodis
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Jesse Mez
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - Michael L. Alosco
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - Victor E. Alvarez
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- VA Boston Healthcare System, Boston, Massachusetts
- VA Bedford Healthcare System, Bedford, Massachusetts
| | - Bertrand R. Huber
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- VA Boston Healthcare System, Boston, Massachusetts
| | - Caroline Kubilus
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Kerry A. Cormier
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- VA Boston Healthcare System, Boston, Massachusetts
- VA Bedford Healthcare System, Bedford, Massachusetts
| | - Raymond Nicks
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Madeline Uretsky
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Evan Nair
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Eva Kuzyk
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Nurgul Aytan
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - Jonathan D. Cherry
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - John F. Crary
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Daniel H. Daneshvar
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts
- Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, Boston, Massachusetts
- Department of Physical Medicine and Rehabilitation, Mass General Brigham-Spaulding Rehabilitation, Charlestown, Massachusetts
| | - Christopher J. Nowinski
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Concussion Legacy Foundation, Boston, Massachusetts
| | - Lee E. Goldstein
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Brigid Dwyer
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- Brain Injury Program, Braintree Rehabilitation Hospital, Braintree, Massachusetts
| | - Douglas I. Katz
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- Brain Injury Program, Braintree Rehabilitation Hospital, Braintree, Massachusetts
| | - Robert C. Cantu
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurosurgery, Emerson Hospital, Concord, Massachusetts
| | - Robert A. Stern
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts
| | - Ann C. McKee
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- VA Boston Healthcare System, Boston, Massachusetts
- VA Bedford Healthcare System, Bedford, Massachusetts
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts
| | - Thor D. Stein
- Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts
- VA Boston Healthcare System, Boston, Massachusetts
- VA Bedford Healthcare System, Bedford, Massachusetts
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts
| |
Collapse
|
17
|
Knowles P, Schneider K, Bugwadia AK, Sorcar P, Pea RD, Daneshvar DH, Baugh CM. The importance of language in describing concussions: A qualitative analysis. PM R 2024. [PMID: 39189352 DOI: 10.1002/pmrj.13256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 06/02/2024] [Accepted: 06/20/2024] [Indexed: 08/28/2024]
Abstract
BACKGROUND Concussions are mild traumatic brain injuries that are often undiagnosed due to difficulties in identifying symptoms. To minimize the negative sequelae associated with undiagnosed concussion, efforts have targeted improving concussion reporting. However, knowing more about concussions does not indicate how likely an athlete is to report their concussion. Alternatively, the attitudes and beliefs of athletes and surrounding stakeholders have shown to be a better indication of whether an athlete intends to report their concussion. Prior research has shown that athletes report concussions less often when the injury is described using language that minimizes their severity, such as when it is referred to as a "ding." This study evaluated whether describing concussions using the word "brain" was associated with individuals' underlying attitudes and beliefs about the injury's severity. OBJECTIVE To measure the relationship between perceived concussion severity and the language used to describe concussions, specifically whether participants used the word "brain" in describing the injury. METHODS One-on-one semi-structured telephone interviews were conducted, and a cross sectional secondary qualitative analysis was performed to assess participants' perceived concussion severity and their use of the word "brain" to describe concussions. DESIGN Cross-sectional secondary qualitative analysis. SETTING One-on-one semistructured telephone interviews. PARTICIPANTS In 2017, 94 individuals involved in high school sports, including athletes, coaches, educators, parents of athletes, and athletic directors were recruited via convenience sampling. MAIN OUTCOME MEASURES Respondents' perceived severity of concussions. RESULTS Individuals who used a brain phrase to describe concussion also perceived concussions as more severe (p < .001). Specifically, those who described concussions with maximum severity had higher odds of using brain phrases than those who described concussions as having minimum (odds ratio [OR] = 0.05, 95% confidence interval [CI] = 0.002-0.299, p < .001) or moderate severity (OR = 0.24, 95% CI = 0.086-0.647, p = .003), with the most significant relationship found among coaches. CONCLUSIONS These findings demonstrate the relationship between medical terminology and perceived severity of concussions. This relationship may play a role in concussion reporting behavior for coaches, athletes, and parents. Education programs using similar medical terminology may promote concussion reporting behaviors.
Collapse
Affiliation(s)
- Peter Knowles
- Department of Psychology, Stanford University, Stanford, California, USA
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
| | - Katherine Schneider
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
- Department of Mechanical Engineering, Stanford University, Stanford, California, USA
| | - Amy K Bugwadia
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
- Stanford University School of Medicine, Stanford, California, USA
| | - Piya Sorcar
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
- Stanford University School of Medicine, Stanford, California, USA
- Stanford Center for Innovation in Global Health, Stanford University, Stanford, California, USA
- Stanford University Graduate School of Education, Stanford University, Stanford, California, USA
| | - Roy D Pea
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
- Stanford University Graduate School of Education, Stanford University, Stanford, California, USA
| | - Daniel H Daneshvar
- TeachAids, Institute for Brain Research and Innovation, Palo Alto, California, USA
- Spaulding Rehabilitation Network, Division of Brain Injury Rehabilitation, Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
- Rehabilitation Outcomes Center at Spaulding, Spaulding Rehabilitation Network, Boston, Massachusetts, USA
| | - Christine M Baugh
- Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| |
Collapse
|
18
|
Clay AM, Carr RL, DuBien JL, To F. Short-term behavioral and histological findings following a single concussive and repeated subconcussive brain injury in a rodent model. Brain Inj 2024; 38:827-834. [PMID: 38704844 DOI: 10.1080/02699052.2024.2349144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 04/23/2024] [Indexed: 05/07/2024]
Abstract
PRIMARY OBJECTIVE It is unclear of the correlation between a mild traumatic brain injury (mTBI) and repeated subconcussive (RSC) impacts with respect to injury biomechanics. Thus, the present study was designed to determine the behavioral and histological differences between a single mTBI impact and RSC impacts with subdivided cumulative kinetic energies of the single mTBI impact. RESEARCH DESIGN Adult male Sprague-Dawley rats were randomly assigned to a single mTBI impact, RSC impact, sham, or repeated sham groups. METHODS AND PROCEDURES Following a weight drop injury, anxiety-like behavior and general locomotive activity and were assessed using the open field test, while motor coordination was evaluated using a rotarod unit. Neuronal loss, astrogliosis, and microgliosis were assessed using NeuN, GFAP and Iba-1 immunohistochemistry. All assessments were undertaken at 3- and 7-days post impact. MAIN OUTCOMES AND RESULTS No behavioral disturbances were observed in injury groups, however, both injury groups did lead to microgliosis following 3-days post-impact. CONCLUSIONS No pathophysiological differences were observed between a single mTBI impact and RSC impacts of the same energy input. Even though a cumulative injury threshold for RSC impacts was not determined, a threshold still may exist where no pathodynamic shift occurs.
Collapse
Affiliation(s)
- Anna Marie Clay
- Department of Agricultural and Biological Engineering, Mississippi State University, Mississippi, USA
| | - Russell L Carr
- Center for Environmental Health Sciences, College of Veterinary Medicine, Mississippi University, Mississippi, USA
| | - Janice L DuBien
- Department of Statistics, Mississippi University, Mississippi, USA
| | - Filip To
- Department of Agricultural and Biological Engineering, Mississippi State University, Mississippi, USA
| |
Collapse
|
19
|
Shoemaker RL, Larsen RJ, Larsen PA. Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research. Front Immunol 2024; 15:1426656. [PMID: 39238639 PMCID: PMC11374656 DOI: 10.3389/fimmu.2024.1426656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Accepted: 07/22/2024] [Indexed: 09/07/2024] Open
Abstract
Neurodegenerative diseases (NDs) in mammals, such as Alzheimer's disease (AD), Parkinson's disease (PD), and transmissible spongiform encephalopathies (TSEs), are characterized by the accumulation of misfolded proteins in the central nervous system (CNS). Despite the presence of these pathogenic proteins, the immune response in affected individuals remains notably muted. Traditional immunological strategies, particularly those reliant on monoclonal antibodies (mAbs), face challenges related to tissue penetration, blood-brain barrier (BBB) crossing, and maintaining protein stability. This has led to a burgeoning interest in alternative immunotherapeutic avenues. Notably, single-domain antibodies (or nanobodies) and aptamers have emerged as promising candidates, as their reduced size facilitates high affinity antigen binding and they exhibit superior biophysical stability compared to mAbs. Aptamers, synthetic molecules generated from DNA or RNA ligands, present both rapid production times and cost-effective solutions. Both nanobodies and aptamers exhibit inherent qualities suitable for ND research and therapeutic development. Cross-seeding events must be considered in both traditional and small-molecule-based immunodiagnostic and therapeutic approaches, as well as subsequent neurotoxic impacts and complications beyond protein aggregates. This review delineates the challenges traditional immunological methods pose in ND research and underscores the potential of nanobodies and aptamers in advancing next-generation ND diagnostics and therapeutics.
Collapse
Affiliation(s)
- Rachel L Shoemaker
- Minnesota Center for Prion Research and Outreach (MNPRO), University of Minnesota, St. Paul, MN, United States
- Department of Biomedical and Veterinary Sciences, University of Minnesota College of Veterinary Medicine, St. Paul, MN, United States
| | - Roxanne J Larsen
- Department of Biomedical and Veterinary Sciences, University of Minnesota College of Veterinary Medicine, St. Paul, MN, United States
- Priogen Corp., St. Paul, MN, United States
| | - Peter A Larsen
- Minnesota Center for Prion Research and Outreach (MNPRO), University of Minnesota, St. Paul, MN, United States
- Department of Biomedical and Veterinary Sciences, University of Minnesota College of Veterinary Medicine, St. Paul, MN, United States
| |
Collapse
|
20
|
Pearson A, Koprivica M, Eisenbaum M, Ortiz C, Browning M, Vincennie T, Tinsley C, Mullan M, Crawford F, Ojo J. PPARγ activation ameliorates cognitive impairment and chronic microglial activation in the aftermath of r-mTBI. J Neuroinflammation 2024; 21:194. [PMID: 39097742 PMCID: PMC11297749 DOI: 10.1186/s12974-024-03173-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 07/12/2024] [Indexed: 08/05/2024] Open
Abstract
Chronic neuroinflammation and microglial activation are key mediators of the secondary injury cascades and cognitive impairment that follow exposure to repetitive mild traumatic brain injury (r-mTBI). Peroxisome proliferator-activated receptor-γ (PPARγ) is expressed on microglia and brain resident myeloid cell types and their signaling plays a major anti-inflammatory role in modulating microglial responses. At chronic timepoints following injury, constitutive PPARγ signaling is thought to be dysregulated, thus releasing the inhibitory brakes on chronically activated microglia. Increasing evidence suggests that thiazolidinediones (TZDs), a class of compounds approved from the treatment of diabetes mellitus, effectively reduce neuroinflammation and chronic microglial activation by activating the peroxisome proliferator-activated receptor-γ (PPARγ). The present study used a closed-head r-mTBI model to investigate the influence of the TZD Pioglitazone on cognitive function and neuroinflammation in the aftermath of r-mTBI exposure. We revealed that Pioglitazone treatment attenuated spatial learning and memory impairments at 6 months post-injury and reduced the expression of reactive microglia and astrocyte markers in the cortex, hippocampus, and corpus callosum. We then examined whether Pioglitazone treatment altered inflammatory signaling mechanisms in isolated microglia and confirmed downregulation of proinflammatory transcription factors and cytokine levels. To further investigate microglial-specific mechanisms underlying PPARγ-mediated neuroprotection, we generated a novel tamoxifen-inducible microglial-specific PPARγ overexpression mouse line and examined its influence on microglial phenotype following injury. Using RNA sequencing, we revealed that PPARγ overexpression ameliorates microglial activation, promotes the activation of pathways associated with wound healing and tissue repair (such as: IL10, IL4 and NGF pathways), and inhibits the adoption of a disease-associated microglia-like (DAM-like) phenotype. This study provides insight into the role of PPARγ as a critical regulator of the neuroinflammatory cascade that follows r-mTBI in mice and demonstrates that the use of PPARγ agonists such as Pioglitazone and newer generation TZDs hold strong therapeutic potential to prevent the chronic neurodegenerative sequelae of r-mTBI.
Collapse
Affiliation(s)
- Andrew Pearson
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA.
- The Open University, Walton Hall, Kents Hill, Milton Keynes, MK7 6AA, UK.
| | - Milica Koprivica
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
| | - Max Eisenbaum
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
- The Open University, Walton Hall, Kents Hill, Milton Keynes, MK7 6AA, UK
| | - Camila Ortiz
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
- The Open University, Walton Hall, Kents Hill, Milton Keynes, MK7 6AA, UK
| | | | - Tessa Vincennie
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
| | - Cooper Tinsley
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
| | - Michael Mullan
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
| | - Fiona Crawford
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
- The Open University, Walton Hall, Kents Hill, Milton Keynes, MK7 6AA, UK
- James A. Haley Veterans' Hospital, 13000 Bruce B Downs Blvd, Tampa, FL, 33612, USA
| | - Joseph Ojo
- The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA
- The Open University, Walton Hall, Kents Hill, Milton Keynes, MK7 6AA, UK
- James A. Haley Veterans' Hospital, 13000 Bruce B Downs Blvd, Tampa, FL, 33612, USA
| |
Collapse
|
21
|
Wallingford A, Junn C. Chronic Traumatic Encephalopathy. Phys Med Rehabil Clin N Am 2024; 35:607-618. [PMID: 38945654 DOI: 10.1016/j.pmr.2024.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/02/2024]
Abstract
This article focuses on neuropathologic diagnostic criteria for chronic traumatic encephalopathy (CTE) and consensus research diagnostic criteria for traumatic encephalopathy syndrome (TES). CTE as a tauopathy has a unique pattern for diagnosis and differs from other neurodegenerative diseases. We discuss the history, neuropathology, and mechanism of CTE as well as the preliminary reasearch diagnostic criteria for TES, which is the proposed clinical presentation of suspected CTE.
Collapse
Affiliation(s)
- Allison Wallingford
- Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA
| | - Cherry Junn
- Department of Rehabilitation Medicine, University of Washington, 325 Ninth Avenue Box 359740, Seattle, WA 98104, USA.
| |
Collapse
|
22
|
Khatib A, Post A, Hoshizaki T, Gilchrist MD. Brain trauma characteristics for lightweight and heavyweight fighters in professional mixed martial arts. Sports Biomech 2024; 23:1083-1105. [PMID: 34011240 DOI: 10.1080/14763141.2021.1922740] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 04/21/2021] [Indexed: 10/21/2022]
Abstract
Mixed martial arts (MMA) is a sport where the fighters are at high risk of brain trauma, with characteristics, such as the frequency, magnitude, and interval of head impacts influencing the risk of developing short- and long-term negative brain health outcomes. These characteristics may be influenced by weight class as they may have unique fighting styles. The purpose of this research was to compare frequency, magnitude, and interval of head impacts between lightweight and heavyweight fighters in professional MMA. Frequency, interval, event type, velocity, and location of head impacts were documented for 60 fighters from 15 Lightweight and 15 Heavyweight professional MMA fights. Head impact reconstructions of these events were performed using physical and finite element modelling methods to determine the strain in the brain tissues. The results found that LW and HW fighters sustained similar head impact frequencies and intervals. The LW fighters sustained a significantly higher frequency of very low and high magnitude impacts to the head from punches; HW a larger frequency of high category strains from elbow strikes. These brain trauma profiles reflect different fight strategies and may inform methods to manage and mitigate the long-term effects of repetitive impacts to the head.
Collapse
Affiliation(s)
- Ali Khatib
- Department of Human Kinetics, University of Ottawa, Ottawa, Canada
| | - Andrew Post
- Department of Human Kinetics, University of Ottawa, Ottawa, Canada
| | | | - Michael D Gilchrist
- Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland
| |
Collapse
|
23
|
Jung LB, Wiegand TLT, Tuz-Zahra F, Tripodis Y, Iliff JJ, Piantino J, Arciniega H, Kim CL, Pankatz L, Bouix S, Lin AP, Alosco ML, Daneshvar DH, Mez J, Sepehrband F, Rathi Y, Pasternak O, Coleman MJ, Adler CH, Bernick C, Balcer L, Cummings JL, Reiman EM, Stern RA, Shenton ME, Koerte IK. Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players. JAMA Netw Open 2024; 7:e2428687. [PMID: 39186275 DOI: 10.1001/jamanetworkopen.2024.28687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/27/2024] Open
Abstract
Importance Exposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role. Objective To investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration. Design, Setting, and Participants This cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses. Exposure Prior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts). Main Outcomes and Measures Individual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume. Results Analyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10-8 [95% CI, 0.50 × 10-8 to 4.93 × 10-8]; P = .03) and CHII-G (β = 2.24 × 10-6 [95% CI, 0.35 × 10-6 to 4.13 × 10-6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = -0.74 [95% CI, -1.35 to -0.13]; P = .04). Conclusions and Relevance These findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.
Collapse
Affiliation(s)
- Leonard B Jung
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
| | - Tim L T Wiegand
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
| | - Fatima Tuz-Zahra
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Yorghos Tripodis
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
- Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University School of Medicine, Boston, Massachusetts
| | - Jeffrey J Iliff
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle
- Department of Neurology, University of Washington School of Medicine, Seattle
- VISN 20 Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Juan Piantino
- Department of Pediatrics, Division of Child Neurology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland
| | - Hector Arciniega
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Rehabilitation Medicine, NYU Grossman School of Medicine, New York, New York
| | - Cara L Kim
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
| | - Lara Pankatz
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
| | - Sylvain Bouix
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Département de génie logiciel et TI, École de technologie supérieure, Université du Québec, Montreal, Canada
| | - Alexander P Lin
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Michael L Alosco
- Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - Daniel H Daneshvar
- Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Jesse Mez
- Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
| | - Farshid Sepehrband
- Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles
| | - Yogesh Rathi
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Ofer Pasternak
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Michael J Coleman
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Charles H Adler
- Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona Scottsdale, Arizona
| | - Charles Bernick
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada
| | - Laura Balcer
- Department of Neurology, NYU Grossman School of Medicine, New York, New York
- Department of Population Health, NYU Grossman School of Medicine, New York, New York
- Department of Ophthalmology, NYU Grossman School of Medicine, New York, New York
| | - Jeffrey L Cummings
- Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas
| | - Eric M Reiman
- Banner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix
| | - Robert A Stern
- Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
- Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, Massachusetts
- Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts
| | - Martha E Shenton
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Inga K Koerte
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston
- Graduate School of Systemic Neurosciences, Ludwig-Maximilians-Universität, Munich, Germany
| |
Collapse
|
24
|
Edelstein R, Gutterman S, Newman B, Van Horn JD. Assessment of Sports Concussion in Female Athletes: A Role for Neuroinformatics? Neuroinformatics 2024:10.1007/s12021-024-09680-8. [PMID: 39078562 DOI: 10.1007/s12021-024-09680-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2024] [Indexed: 07/31/2024]
Abstract
Over the past decade, the intricacies of sports-related concussions among female athletes have become readily apparent. Traditional clinical methods for diagnosing concussions suffer limitations when applied to female athletes, often failing to capture subtle changes in brain structure and function. Advanced neuroinformatics techniques and machine learning models have become invaluable assets in this endeavor. While these technologies have been extensively employed in understanding concussion in male athletes, there remains a significant gap in our comprehension of their effectiveness for female athletes. With its remarkable data analysis capacity, machine learning offers a promising avenue to bridge this deficit. By harnessing the power of machine learning, researchers can link observed phenotypic neuroimaging data to sex-specific biological mechanisms, unraveling the mysteries of concussions in female athletes. Furthermore, embedding methods within machine learning enable examining brain architecture and its alterations beyond the conventional anatomical reference frame. In turn, allows researchers to gain deeper insights into the dynamics of concussions, treatment responses, and recovery processes. This paper endeavors to address the crucial issue of sex differences in multimodal neuroimaging experimental design and machine learning approaches within female athlete populations, ultimately ensuring that they receive the tailored care they require when facing the challenges of concussions. Through better data integration, feature identification, knowledge representation, validation, etc., neuroinformaticists, are ideally suited to bring clarity, context, and explainabilty to the study of sports-related head injuries in males and in females, and helping to define recovery.
Collapse
Affiliation(s)
- Rachel Edelstein
- Department of Psychology, University of Virginia, 409 McCormick Road Gilmer Hall Room 304, Charlottesville, VA, 22904, USA.
| | - Sterling Gutterman
- Department of Psychology, University of Virginia, 409 McCormick Road Gilmer Hall Room 304, Charlottesville, VA, 22904, USA
| | - Benjamin Newman
- Department of Psychology, University of Virginia, 409 McCormick Road Gilmer Hall Room 304, Charlottesville, VA, 22904, USA
| | - John Darrell Van Horn
- Department of Psychology, University of Virginia, 409 McCormick Road Gilmer Hall Room 304, Charlottesville, VA, 22904, USA
| |
Collapse
|
25
|
Tak H, Anirudh J, Chattopadhyay A, Naick BH. Argonaute protein assisted drug discovery for miRNA-181c-5p and target gene ATM translation repression: a computational approach. Mol Divers 2024:10.1007/s11030-024-10855-3. [PMID: 39026118 DOI: 10.1007/s11030-024-10855-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Accepted: 03/21/2024] [Indexed: 07/20/2024]
Abstract
The miRNA binds to AGO's seed region, prompting the exploration of small molecules that can offset miRNA repression of target mRNA. This miRNA-181c-5p was found to be upregulated in the chronic traumatic encephalopathy, a prevalent neurodegenerative disease in contact sports and military personals. The research aimed to identify compounds that disrupt the AGO-assisted loop formation between miRNA-181c-5p and ATM, consequently repressing the translation of ATM. Target genes from commonly three databases (DIANA-microT-CDS, miRDB, RNA22 and TargetScan) were subjected to functional annotation and clustering analysis using DAVID bioinformatics tool. Haddock server were employed to make miRNA-181c-5p:ATM-AGO complex. A total of 2594 small molecules were screened using Glide XP based on their highest binding affinity towards the complex, through a three-phase docking approach. The top 5 compounds (DB00674-Galantamine, DB00371-Meprobamate, DB00694-Daunorubicin, DB00837-Progabide, and DB00851-Dacarbazine) were further analyzed for stability in the miRNA-181c-5p:ATM-AGO-ligand complex interaction using GROMACS (version 2023.2). Hence, these findings suggest that these molecules hold potential for facilitating AGO-assisted repression of ATM gene translation.
Collapse
Affiliation(s)
- Harshita Tak
- Department of Sports Biosciences, School of Sports Science, Central University of Rajasthan, Ajmer, India
| | - Jivanage Anirudh
- Department of Sports Biosciences, School of Sports Science, Central University of Rajasthan, Ajmer, India
| | - Arpan Chattopadhyay
- Department of Sports Biosciences, School of Sports Science, Central University of Rajasthan, Ajmer, India
| | - B Hemanth Naick
- Department of Sports Biosciences, School of Sports Science, Central University of Rajasthan, Ajmer, India.
| |
Collapse
|
26
|
Finan JD, Vogt TE, Samei Y. Cavitation in blunt impact traumatic brain injury. EXPERIMENTS IN FLUIDS 2024; 65:114. [PMID: 39036013 PMCID: PMC11255084 DOI: 10.1007/s00348-024-03853-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Revised: 06/29/2024] [Accepted: 07/04/2024] [Indexed: 07/23/2024]
Abstract
Traumatic brain injury (TBI) poses a major public health challenge. No proven therapies for the condition exist so protective equipment that prevents or mitigates these injuries plays a critical role in minimizing the societal burden of this condition. Our ability to optimize protective equipment depends on our capacity to relate the mechanics of head impact events to morbidity and mortality. This capacity, in turn, depends on correctly identifying the mechanisms of injury. For several decades, a controversial theory of TBI biomechanics has attributed important classes of injury to cavitation inside the cranial vault during blunt impact. This theory explains counter-intuitive clinical observations, including the coup-contre-coup pattern of injury. However, it is also difficult to validate experimentally in living subjects. Also, blunt impact TBI is a broad term that covers a range of different head impact events, some of which may be better described by cavitation theory than others. This review surveys what has been learned about cavitation through mathematical modeling, physical modeling, and experimentation with living tissues and places it in context with competing theories of blunt injury biomechanics and recent research activity in the field in an attempt to understand what the theory has to offer the next generation of innovators in TBI biomechanics.
Collapse
Affiliation(s)
- John D. Finan
- Department of Mechanical and Industrial Engineering, University of Illinois Chicago, Chicago, IL USA
| | - Thea E. Vogt
- Department of Mechanical and Industrial Engineering, University of Illinois Chicago, Chicago, IL USA
| | - Yasaman Samei
- Department of Mechanical and Industrial Engineering, University of Illinois Chicago, Chicago, IL USA
| |
Collapse
|
27
|
Dybing KM, McAllister TW, Wu YC, McDonald BC, Broglio SP, Mihalik JP, Guskiewicz KM, Goldman JT, Jackson JC, Risacher SL, Saykin AJ, Nudelman KNH. Association of Alzheimer's disease polygenic risk score with concussion severity and recovery metrics. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.07.10.24309042. [PMID: 39040205 PMCID: PMC11261937 DOI: 10.1101/2024.07.10.24309042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/24/2024]
Abstract
Identification of genetic alleles associated with both Alzheimer's disease (AD) and concussion severity/recovery could help explain the association between concussion and elevated dementia risk. However, there has been little investigation into whether AD risk genes associate with concussion severity/recovery, and the limited findings are mixed. We used AD polygenic risk scores (PRS) and APOE genotypes to investigate any such associations in the NCAA-DoD Grand Alliance CARE Consortium (CARE) dataset. We assessed six outcomes in 931 total participants. The outcomes were two concussion recovery measures (number of days to asymptomatic status, number of days to return to play (RTP)) and four concussion severity measures (scores on SAC and BESS, SCAT symptom severity, and total number of symptoms). We calculated PRS using a published score [1] and performed multiple linear regression (MLR) to assess the relationship of PRS with the outcomes. We also used t-tests and chi-square tests to examine outcomes by APOE genotype, and MLR to analyze outcomes in European and African genetic ancestry subgroups. Higher PRS was associated with longer injury to RTP in the normal RTP (<24 days) subgroup ( p = 0.024), and one standard deviation increase in PRS resulted in a 9.89 hour increase to the RTP interval. There were no other consistently significant effects, suggesting that high AD genetic risk is not strongly associated with more severe concussions or poor recovery in young adults. Future studies should attempt to replicate these findings in larger samples with longer follow-up using PRS calculated from diverse populations.
Collapse
|
28
|
Garcia-Cordero I, Vasilevskaya A, Taghdiri F, Khodadadi M, Mikulis D, Tarazi A, Mushtaque A, Anssari N, Colella B, Green R, Rogaeva E, Sato C, Grinberg M, Moreno D, Hussain MW, Blennow K, Zetterberg H, Davis KD, Wennberg R, Tator C, Tartaglia MC. Functional connectivity changes in neurodegenerative biomarker-positive athletes with repeated concussions. J Neurol 2024; 271:4180-4190. [PMID: 38589629 DOI: 10.1007/s00415-024-12340-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/27/2024] [Accepted: 03/19/2024] [Indexed: 04/10/2024]
Abstract
Multimodal biomarkers may identify former contact sports athletes with repeated concussions and at risk for dementia. Our study aims to investigate whether biomarker evidence of neurodegeneration in former professional athletes with repetitive concussions (ExPro) is associated with worse cognition and mood/behavior, brain atrophy, and altered functional connectivity. Forty-one contact sports athletes with repeated concussions were divided into neurodegenerative biomarker-positive (n = 16) and biomarker-negative (n = 25) groups based on positivity of serum neurofilament light-chain. Six healthy controls (negative for biomarkers) with no history of concussions were also analyzed. We calculated cognitive and mood/behavior composite scores from neuropsychological assessments. Gray matter volume maps and functional connectivity of the default mode, salience, and frontoparietal networks were compared between groups using ANCOVAs, controlling for age, and total intracranial volume. The association between the connectivity networks and sports characteristics was analyzed by multiple regression analysis in all ExPro. Participants presented normal-range mean performance in executive function, memory, and mood/behavior tests. The ExPro groups did not differ in professional years played, age at first participation in contact sports, and number of concussions. There were no differences in gray matter volume between groups. The neurodegenerative biomarker-positive group had lower connectivity in the default mode network (DMN) compared to the healthy controls and the neurodegenerative biomarker-negative group. DMN disconnection was associated with increased number of concussions in all ExPro. Biomarkers of neurodegeneration may be useful to detect athletes that are still cognitively normal, but with functional connectivity alterations after concussions and at risk of dementia.
Collapse
Affiliation(s)
- Indira Garcia-Cordero
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Anna Vasilevskaya
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Foad Taghdiri
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Mozhgan Khodadadi
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - David Mikulis
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Apameh Tarazi
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Asma Mushtaque
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Neda Anssari
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
- Brain Vision and Concussion Clinic, Winnipeg, Canada
| | - Brenda Colella
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Robin Green
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Ekaterina Rogaeva
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Christine Sato
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Mark Grinberg
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Danielle Moreno
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Mohammed W Hussain
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
- UK Dementia Research Institute at UCL, London, UK
- Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
| | - Karen D Davis
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
- Krembil Brain Institute, University Health Network, Toronto, Canada
- Department of Surgery, University of Toronto, Toronto, Canada
- Institute of Medical Science, University of Toronto, Toronto, Canada
| | - Richard Wennberg
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Charles Tator
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
| | - Maria C Tartaglia
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
- Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Canada.
| |
Collapse
|
29
|
Fernandes GCDAM, Lima EBDS, Lara PHS, Gandolfi ACDC, Pagura JR, Arliani GG, Cohen M. Sport-related concussion in Brazilian professional soccer: A four-year prospective epidemiological analysis. SPORTS MEDICINE AND HEALTH SCIENCE 2024. [DOI: 10.1016/j.smhs.2024.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/08/2024] Open
|
30
|
Lindberg A, Murrell E, Tong J, Mason NS, Sohn D, Sandell J, Ström P, Stehouwer JS, Lopresti BJ, Viklund J, Svensson S, Mathis CA, Vasdev N. Ligand-based design of [ 18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies. Nat Commun 2024; 15:5109. [PMID: 38877019 PMCID: PMC11178805 DOI: 10.1038/s41467-024-49258-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 05/30/2024] [Indexed: 06/16/2024] Open
Abstract
Positron emission tomography (PET) imaging of tau aggregation in Alzheimer's disease (AD) is helping to map and quantify the in vivo progression of AD pathology. To date, no high-affinity tau-PET radiopharmaceutical has been optimized for imaging non-AD tauopathies. Here we show the properties of analogues of a first-in-class 4R-tau lead, [18F]OXD-2115, using ligand-based design. Over 150 analogues of OXD-2115 were synthesized and screened in post-mortem brain tissue for tau affinity against [3H]OXD-2115, and in silico models were used to predict brain uptake. [18F]OXD-2314 was identified as a selective, high-affinity non-AD tau PET radiotracer with favorable brain uptake, dosimetry, and radiometabolite profiles in rats and non-human primate and is being translated for first-in-human PET studies.
Collapse
Affiliation(s)
- Anton Lindberg
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
| | - Emily Murrell
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Junchao Tong
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
| | - N Scott Mason
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Daniel Sohn
- Oxiant Discovery, SE-15136, Södertälje, Sweden
| | | | - Peter Ström
- Novandi Chemistry AB, SE-15136, Södertälje, Sweden
| | | | - Brian J Lopresti
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
| | | | | | - Chester A Mathis
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
| | - Neil Vasdev
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
- Department of Psychiatry, University of Toronto, Toronto, Canada.
| |
Collapse
|
31
|
Irastorza-Valera L, Soria-Gómez E, Benitez JM, Montáns FJ, Saucedo-Mora L. Review of the Brain's Behaviour after Injury and Disease for Its Application in an Agent-Based Model (ABM). Biomimetics (Basel) 2024; 9:362. [PMID: 38921242 PMCID: PMC11202129 DOI: 10.3390/biomimetics9060362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 05/28/2024] [Accepted: 06/05/2024] [Indexed: 06/27/2024] Open
Abstract
The brain is the most complex organ in the human body and, as such, its study entails great challenges (methodological, theoretical, etc.). Nonetheless, there is a remarkable amount of studies about the consequences of pathological conditions on its development and functioning. This bibliographic review aims to cover mostly findings related to changes in the physical distribution of neurons and their connections-the connectome-both structural and functional, as well as their modelling approaches. It does not intend to offer an extensive description of all conditions affecting the brain; rather, it presents the most common ones. Thus, here, we highlight the need for accurate brain modelling that can subsequently be used to understand brain function and be applied to diagnose, track, and simulate treatments for the most prevalent pathologies affecting the brain.
Collapse
Affiliation(s)
- Luis Irastorza-Valera
- E.T.S. de Ingeniería Aeronáutica y del Espacio, Universidad Politécnica de Madrid, Pza. Cardenal Cisneros 3, 28040 Madrid, Spain; (L.I.-V.); (J.M.B.); (F.J.M.)
- PIMM Laboratory, ENSAM–Arts et Métiers ParisTech, 151 Bd de l’Hôpital, 75013 Paris, France
| | - Edgar Soria-Gómez
- Achúcarro Basque Center for Neuroscience, Barrio Sarriena, s/n, 48940 Leioa, Spain;
- Ikerbasque, Basque Foundation for Science, Plaza Euskadi, 5, 48009 Bilbao, Spain
- Department of Neurosciences, University of the Basque Country UPV/EHU, Barrio Sarriena, s/n, 48940 Leioa, Spain
| | - José María Benitez
- E.T.S. de Ingeniería Aeronáutica y del Espacio, Universidad Politécnica de Madrid, Pza. Cardenal Cisneros 3, 28040 Madrid, Spain; (L.I.-V.); (J.M.B.); (F.J.M.)
| | - Francisco J. Montáns
- E.T.S. de Ingeniería Aeronáutica y del Espacio, Universidad Politécnica de Madrid, Pza. Cardenal Cisneros 3, 28040 Madrid, Spain; (L.I.-V.); (J.M.B.); (F.J.M.)
- Department of Mechanical and Aerospace Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville, FL 32611, USA
| | - Luis Saucedo-Mora
- E.T.S. de Ingeniería Aeronáutica y del Espacio, Universidad Politécnica de Madrid, Pza. Cardenal Cisneros 3, 28040 Madrid, Spain; (L.I.-V.); (J.M.B.); (F.J.M.)
- Department of Materials, University of Oxford, Parks Road, Oxford OX1 3PJ, UK
- Department of Nuclear Science and Engineering, Massachusetts Institute of Technology (MIT), 77 Massachusetts Ave, Cambridge, MA 02139, USA
| |
Collapse
|
32
|
Werner JK. Is neurotrauma-related rapid eye movement behavior disorder a harbinger of synucleinopathy? Sleep 2024; 47:zsae060. [PMID: 38436612 DOI: 10.1093/sleep/zsae060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Indexed: 03/05/2024] Open
Affiliation(s)
- J Kent Werner
- Department of Neurology, Uniformed Services University, Bethesda, MD, USA
- Department of Neurology, Walter Reed National Military Medical Center, Bethesda, MD, USA
- Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
33
|
Ye Z, Li Z, Zhong S, Xing Q, Li K, Sheng W, Shi X, Bao Y. The recent two decades of traumatic brain injury: a bibliometric analysis and systematic review. Int J Surg 2024; 110:3745-3759. [PMID: 38608040 PMCID: PMC11175772 DOI: 10.1097/js9.0000000000001367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 03/10/2024] [Indexed: 04/14/2024]
Abstract
BACKGROUND Traumatic brain injury (TBI) is a serious public health burden worldwide, with a mortality rate of 20-30%; however, reducing the incidence and mortality rates of TBI remains a major challenge. This study provides a multidimensional analysis to explore the potential breakthroughs in TBI over the past two decades. MATERIALS AND METHODS The authors used bibliometric and Latent Dirichlet Allocation (LDA) analyses to analyze publications focusing on TBI published between 2003 and 2022 from the Web of Science Core Collection (WOSCC) database to identify core journals and collaborations among countries/regions, institutions, authors, and research trends. RESULTS Over the past 20 years, 41 545 articles on TBI from 3043 journals were included, with 12 916 authors from 20 449 institutions across 145 countries/regions. The annual number of publications has increased 10-fold compared to previous publications. This study revealed that high-income countries, especially the United States, have a significant influence. Collaboration was limited to several countries/regions. The LDA results indicated that the hotspots included four main areas: 'Clinical finding', 'Molecular mechanism', 'Epidemiology', and 'Prognosis'. Epidemiological research has consistently increased in recent years. Through epidemiological topic analysis, the main etiology of TBI has shifted from traffic accidents to falls in a demographically aging society. CONCLUSION Over the past two decades, TBI research has developed rapidly, and its epidemiology has received increasing attention. Reducing the incidence of TBI from a preventive perspective is emerging as a trend to alleviate the future social burden; therefore, epidemiological research might bring breakthroughs in TBI.
Collapse
Affiliation(s)
- Ziyin Ye
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| | - Zhi Li
- Department of Oncology, The First Hospital of China Medical University, Heping
| | - Shiyu Zhong
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| | - Qichen Xing
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| | - Kunhang Li
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| | - Weichen Sheng
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| | - Xin Shi
- School of Health Management, China Medical University, Shenyang, People’s Republic of China
| | - Yijun Bao
- Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu
| |
Collapse
|
34
|
Abyadeh M, Gupta V, Paulo JA, Mahmoudabad AG, Shadfar S, Mirshahvaladi S, Gupta V, Nguyen CT, Finkelstein DI, You Y, Haynes PA, Salekdeh GH, Graham SL, Mirzaei M. Amyloid-beta and tau protein beyond Alzheimer's disease. Neural Regen Res 2024; 19:1262-1276. [PMID: 37905874 PMCID: PMC11467936 DOI: 10.4103/1673-5374.386406] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 08/08/2023] [Accepted: 09/07/2023] [Indexed: 11/02/2023] Open
Abstract
ABSTRACT The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to play key roles in Alzheimer's disease pathogenesis and are considered the main pathological hallmarks of this devastating disease. Physiologically, these two proteins are produced and expressed within the normal human body. However, under pathological conditions, abnormal expression, post-translational modifications, conformational changes, and truncation can make these proteins prone to aggregation, triggering specific disease-related cascades. Recent studies have indicated associations between aberrant behavior of amyloid-beta and tau proteins and various neurological diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, these proteins have been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes, which are all leading causes of morbidity and mortality. In this comprehensive review, we provide an overview of the connections between amyloid-beta and tau proteins and a spectrum of disorders.
Collapse
Affiliation(s)
| | - Vivek Gupta
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| | - Joao A. Paulo
- Department of Cell Biology, Harvard Medical School, Boston, MA, USA
| | | | - Sina Shadfar
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| | - Shahab Mirshahvaladi
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| | - Veer Gupta
- School of Medicine, Deakin University, Geelong, VIC, Australia
| | - Christine T.O. Nguyen
- Department of Optometry and Vision Sciences, School of Health Sciences, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
| | - David I. Finkelstein
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Yuyi You
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| | - Paul A. Haynes
- School of Natural Sciences, Macquarie University, Macquarie Park, NSW, Australia
| | - Ghasem H. Salekdeh
- School of Natural Sciences, Macquarie University, Macquarie Park, NSW, Australia
| | - Stuart L. Graham
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| | - Mehdi Mirzaei
- Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Macquarie Park, North Ryde, Sydney, NSW, Australia
| |
Collapse
|
35
|
Taghdiri F, Khodadadi M, Sadia N, Mushtaque A, Scott OFT, Hirsch‐Reinhagen V, Tator C, Wennberg R, Kovacs GG, Tartaglia MC. Unusual combinations of neurodegenerative pathologies with chronic traumatic encephalopathy (CTE) complicates clinical prediction of CTE. Eur J Neurol 2024; 31:e16259. [PMID: 38404144 PMCID: PMC11235773 DOI: 10.1111/ene.16259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 01/27/2024] [Accepted: 02/08/2024] [Indexed: 02/27/2024]
Abstract
BACKGROUND AND PURPOSE Chronic traumatic encephalopathy (CTE) has gained widespread attention due to its association with multiple concussions and contact sports. However, CTE remains a postmortem diagnosis, and the link between clinical symptoms and CTE pathology is poorly understood. This study aimed to investigate the presence of copathologies and their impact on symptoms in former contact sports athletes. METHODS This was a retrospective case series design of 12 consecutive cases of former contact sports athletes referred for autopsy. Analyses are descriptive and include clinical history as well as the pathological findings of the autopsied brains. RESULTS All participants had a history of multiple concussions, and all but one had documented progressive cognitive, psychiatric, and/or motor symptoms. The results showed that 11 of the 12 participants had evidence of CTE in the brain, but also other copathologies, including different combinations of tauopathies, and other rare entities. CONCLUSIONS The heterogeneity of symptoms after repetitive head injuries and the diverse pathological combinations accompanying CTE complicate the prediction of CTE in clinical practice. It is prudent to consider the possibility of multiple copathologies when clinically assessing patients with repetitive head injuries, especially as they age, and attributing neurological or cognitive symptoms solely to presumptive CTE in elderly patients should be discouraged.
Collapse
Affiliation(s)
- Foad Taghdiri
- Tanz Centre for Research in Neurodegenerative DiseaseUniversity of TorontoTorontoOntarioCanada
| | - Mozhgan Khodadadi
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
| | - Nusrat Sadia
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
| | - Asma Mushtaque
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
| | - Olivia F. T. Scott
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
| | - Veronica Hirsch‐Reinhagen
- Division of NeuropathologyVancouver General HospitalVancouverBritish ColumbiaCanada
- Department of Pathology and Laboratory MedicineUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | - Charles Tator
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
- Krembil Brain InstituteUniversity Health NetworkTorontoOntarioCanada
| | - Richard Wennberg
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
- Krembil Brain InstituteUniversity Health NetworkTorontoOntarioCanada
| | - Gabor G. Kovacs
- Tanz Centre for Research in Neurodegenerative DiseaseUniversity of TorontoTorontoOntarioCanada
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
- Krembil Brain InstituteUniversity Health NetworkTorontoOntarioCanada
- Laboratory Medicine ProgramUniversity Health NetworkTorontoOntarioCanada
- Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoOntarioCanada
- Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders ClinicToronto Western HospitalTorontoOntarioCanada
| | - M. Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative DiseaseUniversity of TorontoTorontoOntarioCanada
- Canadian Concussion CentreKrembil Brain Institute, University Health NetworkTorontoOntarioCanada
- Krembil Brain InstituteUniversity Health NetworkTorontoOntarioCanada
| |
Collapse
|
36
|
Markicevic M, Mandino F, Toyonaga T, Cai Z, Fesharaki-Zadeh A, Shen X, Strittmatter SM, Lake E. Repetitive mild closed-head injury induced synapse loss and increased local BOLD-fMRI signal homogeneity. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.05.24.595651. [PMID: 38826468 PMCID: PMC11142233 DOI: 10.1101/2024.05.24.595651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2024]
Abstract
Repeated mild head injuries due to sports, or domestic violence and military service are increasingly linked to debilitating symptoms in the long term. Although symptoms may take decades to manifest, potentially treatable neurobiological alterations must begin shortly after injury. Better means to diagnose and treat traumatic brain injuries, requires an improved understanding of the mechanisms underlying progression and means through which they can be measured. Here, we employ a repetitive mild closed-head injury (rmTBI) and chronic variable stress (CVS) mouse model to investigate emergent structural and functional brain abnormalities. Brain imaging is achieved with [ 18 F]SynVesT-1 positron emission tomography, with the synaptic vesicle glycoprotein 2A ligand marking synapse density and BOLD (blood-oxygen-level-dependent) functional magnetic resonance imaging (fMRI). Animals were scanned six weeks after concluding rmTBI/Stress procedures. Injured mice showed widespread decreases in synaptic density coupled with an i ncrease in local BOLD-fMRI synchrony detected as regional homogeneity. Injury-affected regions with higher synapse density showed a greater increase in fMRI regional homogeneity. Taken together, these observations may reflect compensatory mechanisms following injury. Multimodal studies are needed to provide deeper insights into these observations.
Collapse
|
37
|
Barbas H, Garcia-Cabezas MA, John Y, Bautista J, McKee A, Zikopoulos B. Cortical circuit principles predict patterns of trauma induced tauopathy in humans. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.05.02.592271. [PMID: 38746103 PMCID: PMC11092596 DOI: 10.1101/2024.05.02.592271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2024]
Abstract
Connections in the cortex of diverse mammalian species are predicted reliably by the Structural Model for direction of pathways and signal processing (reviewed in 1,2). The model is rooted in the universal principle of cortical systematic variation in laminar structure and has been supported widely for connection patterns in animals but has not yet been tested for humans. Here, in postmortem brains of individuals neuropathologically diagnosed with chronic traumatic encephalopathy (CTE) we studied whether the hyperphosphorylated tau (p-tau) pathology parallels connection sequence in time by circuit mechanisms. CTE is a progressive p-tau pathology that begins focally in perivascular sites in sulcal depths of the neocortex (stages I-II) and later involves the medial temporal lobe (MTL) in stages III-IV. We provide novel quantitative evidence that the p-tau pathology in MTL A28 and nearby sites in CTE stage III closely follows the graded laminar patterns seen in homologous cortico-cortical connections in non-human primates. The Structural Model successfully predicted the laminar distribution of the p-tau neurofibrillary tangles and neurites and their density, based on the relative laminar (dis)similarity between the cortical origin (seed) and each connection site. The findings were validated for generalizability by a computational progression model. By contrast, the early focal perivascular pathology in the sulcal depths followed local columnar connectivity rules. These findings support the general applicability of a theoretical model to unravel the direction and progression of p-tau pathology in human neurodegeneration via a cortico-cortical mechanism. Cortical pathways converging on medial MTL help explain the progressive spread of p-tau pathology from focal cortical sites in early CTE to widespread lateral MTL areas and beyond in later disease stages.
Collapse
Affiliation(s)
- Helen Barbas
- Neural Systems Laboratory, Department of Health Sciences, Boston University, Boston, MA 022152
- Graduate Program in Neuroscience, Boston Univ. and School of Medicine
- Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA
- Center for Systems Neuroscience, Boston University, Boston, MA
| | - Miguel Angel Garcia-Cabezas
- Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
| | - Yohan John
- Neural Systems Laboratory, Department of Health Sciences, Boston University, Boston, MA 022152
| | - Julied Bautista
- Neural Systems Laboratory, Department of Health Sciences, Boston University, Boston, MA 022152
| | - Ann McKee
- Veterans Affairs (VA) Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts
- Alzheimer’s Disease Research Center and Chronic Traumatic Encephalopathy Center, Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts
| | - Basilis Zikopoulos
- Graduate Program in Neuroscience, Boston Univ. and School of Medicine
- Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA
- Center for Systems Neuroscience, Boston University, Boston, MA
- Human Systems Neuroscience Laboratory, Department of Health Sciences, Boston University
| |
Collapse
|
38
|
Wang B, Pan X, Teng IT, Li X, Kobeissy F, Wu ZY, Zhu J, Cai G, Yan H, Yan X, Liang M, Yu F, Lu J, Yang Z, Biondi E, Haskins W, Cao YC, Benner SA, Tan W, Wang KK. Functional Selection of Tau Oligomerization-Inhibiting Aptamers. Angew Chem Int Ed Engl 2024; 63:e202402007. [PMID: 38407551 DOI: 10.1002/anie.202402007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 02/19/2024] [Accepted: 02/21/2024] [Indexed: 02/27/2024]
Abstract
Pathological hyperphosphorylation and aggregation of microtubule-associated Tau protein contribute to Alzheimer's Disease (AD) and other related tauopathies. Currently, no cure exists for Alzheimer's Disease. Aptamers offer significant potential as next-generation therapeutics in biotechnology and the treatment of neurological disorders. Traditional aptamer selection methods for Tau protein focus on binding affinity rather than interference with pathological Tau. In this study, we developed a new selection strategy to enrich DNA aptamers that bind to surviving monomeric Tau protein under conditions that would typically promote Tau aggregation. Employing this approach, we identified a set of aptamer candidates. Notably, BW1c demonstrates a high binding affinity (Kd=6.6 nM) to Tau protein and effectively inhibits arachidonic acid (AA)-induced Tau protein oligomerization and aggregation. Additionally, it inhibits GSK3β-mediated Tau hyperphosphorylation in cell-free systems and okadaic acid-mediated Tau hyperphosphorylation in cellular milieu. Lastly, retro-orbital injection of BW1c tau aptamer shows the ability to cross the blood brain barrier and gain access to neuronal cell body. Through further refinement and development, these Tau aptamers may pave the way for a first-in-class neurotherapeutic to mitigate tauopathy-associated neurodegenerative disorders.
Collapse
Affiliation(s)
- Bang Wang
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
- Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA
| | - Xiaoshu Pan
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - I-Ting Teng
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Xiaowei Li
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Firas Kobeissy
- Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA
| | - Zo-Yu Wu
- Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA
| | - Jiepei Zhu
- Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA
| | - Guangzheng Cai
- Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA
| | - He Yan
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Xin Yan
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Mingwei Liang
- Department of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Fahong Yu
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Jianrong Lu
- Department of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Zunyi Yang
- Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA
| | - Elisa Biondi
- Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA
| | - William Haskins
- Gryphon Bio, Inc., 611 Gateway Blvd. Suite 120 #253, South San Francisco, CA 94080-7066, USA
| | - Y Charles Cao
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
| | - Steven A Benner
- Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA
| | - Weihong Tan
- Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, 410082, China
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China
| | - Kevin K Wang
- Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA
- Gryphon Bio, Inc., 611 Gateway Blvd. Suite 120 #253, South San Francisco, CA 94080-7066, USA
- Brain Rehabilitation Research Center, Malcom Randall VA Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL 32608, USA
| |
Collapse
|
39
|
Zimmerman KA, Hain JA, Graham NSN, Rooney EJ, Lee Y, Del-Giovane M, Parker TD, Friedland D, Cross MJ, Kemp S, Wilson MG, Sylvester RJ, Sharp DJ. Prospective cohort study of long-term neurological outcomes in retired elite athletes: the Advanced BiomaRker, Advanced Imaging and Neurocognitive (BRAIN) Health Study protocol. BMJ Open 2024; 14:e082902. [PMID: 38663922 PMCID: PMC11043776 DOI: 10.1136/bmjopen-2023-082902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 03/26/2024] [Indexed: 04/28/2024] Open
Abstract
INTRODUCTION Although limited, recent research suggests that contact sport participation might have an adverse long-term effect on brain health. Further work is required to determine whether this includes an increased risk of neurodegenerative disease and/or subsequent changes in cognition and behaviour. The Advanced BiomaRker, Advanced Imaging and Neurocognitive Health Study will prospectively examine the neurological, psychiatric, psychological and general health of retired elite-level rugby union and association football/soccer players. METHODS AND ANALYSIS 400 retired athletes will be recruited (200 rugby union and 200 association football players, male and female). Athletes will undergo a detailed clinical assessment, advanced neuroimaging, blood testing for a range of brain health outcomes and neuropsychological assessment longitudinally. Follow-up assessments will be completed at 2 and 4 years after baseline visit. 60 healthy volunteers will be recruited and undergo an aligned assessment protocol including advanced neuroimaging, blood testing and neuropsychological assessment. We will describe the previous exposure to head injuries across the cohort and investigate relationships between biomarkers of brain injury and clinical outcomes including cognitive performance, clinical diagnoses and psychiatric symptom burden. ETHICS AND DISSEMINATION Relevant ethical approvals have been granted by the Camberwell St Giles Research Ethics Committee (Ref: 17/LO/2066). The study findings will be disseminated through manuscripts in clinical/academic journals, presentations at professional conferences and through participant and stakeholder communications.
Collapse
Affiliation(s)
- Karl A Zimmerman
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Centre for Injury Studies, Imperial College London, London, UK
| | - Jessica A Hain
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
| | - Neil S N Graham
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Centre for Injury Studies, Imperial College London, London, UK
| | - Erin Jane Rooney
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Institute of Sport, Exercise and Health (ISEH), University College London, London, UK
| | - Ying Lee
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Institute of Sport, Exercise and Health (ISEH), University College London, London, UK
| | - Martina Del-Giovane
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
| | - Thomas D Parker
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
| | - Daniel Friedland
- Department of Brain Sciences, Imperial College London, London, UK
- Institute of Sport, Exercise and Health (ISEH), University College London, London, UK
| | - Matthew J Cross
- Carnegie Applied Rugby Research Centre, Carnegie School of Sport, Leeds Beckett University, Leeds, UK
- Premiership Rugby, London, UK
| | - Simon Kemp
- Rugby Football Union, Twickenham, UK
- London School of Hygiene & Tropical Medicine, London, UK
| | - Mathew G Wilson
- Institute of Sport, Exercise and Health (ISEH), University College London, London, UK
- HCA Healthcare Research Institute, London, UK
| | - Richard J Sylvester
- Institute of Sport, Exercise and Health (ISEH), University College London, London, UK
- Acute Stroke and Brain Injury Unit, National Hospital for Neurology and Neurosurgery, London, UK
| | - David J Sharp
- Centre for Care, Research and Technology, UK Dementia Research Institute, Imperial College London, London, UK
- Department of Brain Sciences, Imperial College London, London, UK
- Centre for Injury Studies, Imperial College London, London, UK
| |
Collapse
|
40
|
Pszczołowska M, Walczak K, Miśków W, Antosz K, Batko J, Kurpas D, Leszek J. Chronic Traumatic Encephalopathy as the Course of Alzheimer's Disease. Int J Mol Sci 2024; 25:4639. [PMID: 38731858 PMCID: PMC11083609 DOI: 10.3390/ijms25094639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Revised: 04/15/2024] [Accepted: 04/19/2024] [Indexed: 05/13/2024] Open
Abstract
This editorial investigates chronic traumatic encephalopathy (CTE) as a course of Alzheimer's disease (AD). CTE is a debilitating neurodegenerative disease that is the result of repeated mild traumatic brain injury (TBI). Many epidemiological studies show that experiencing a TBI in early or middle life is associated with an increased risk of dementia later in life. Chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD) present a series of similar neuropathological features that were investigated in this work like recombinant tau into filaments or the accumulation and aggregation of Aβ protein. However, these two conditions differ from each other in brain-blood barrier damage. The purpose of this review was to evaluate information about CTE and AD from various articles, focusing especially on new therapeutic possibilities for the improvement in cognitive skills.
Collapse
Affiliation(s)
- Magdalena Pszczołowska
- Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland; (M.P.)
| | - Kamil Walczak
- Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland; (M.P.)
| | - Weronika Miśków
- Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland; (M.P.)
| | - Katarzyna Antosz
- Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland; (M.P.)
| | - Joanna Batko
- Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland; (M.P.)
| | - Donata Kurpas
- Faculty of Health Sciences, Wroclaw Medical University, Ul. Kazimierza Bartla 5, 51-618 Wrocław, Poland
| | - Jerzy Leszek
- Clinic of Psychiatry, Department of Psychiatry, Wroclaw Medical University, Ludwika Pasteura 10, 50-367 Wrocław, Poland
| |
Collapse
|
41
|
Iverson GL, Gardner AJ, Castellani RJ, Kissinger-Knox A. Applying the Consensus Criteria for Traumatic Encephalopathy Syndrome Retrospectively to Case Studies of Boxers from the 20th Century. Neurotrauma Rep 2024; 5:337-347. [PMID: 38595792 PMCID: PMC11002329 DOI: 10.1089/neur.2023.0134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/11/2024] Open
Abstract
There are no validated diagnostic criteria for traumatic encephalopathy syndrome (TES). During the early and middle 20th century, TES was described as a clinical condition that was experienced by some high-exposure boxers-and it was believed to reflect chronic traumatic brain injury. Consensus criteria for the diagnosis of TES were published in 2021. We applied the consensus criteria for TES retrospectively to cases of chronic brain damage in boxers described in articles published in the 20th century that were obtained from narrative and systematic reviews. The sample included 157 boxers identified in 21 articles published between 1929 and 1999. Two authors reviewed each case description and coded the criteria for TES. For the core clinical features, cognitive impairment was noted in 63.1%, and in 28.7% of cases the person's cognitive functioning appeared to be broadly normal. Neurobehavioral dysregulation was present in 25.5%. One third (34.4%) were identified as progressive, 30.6% were not progressive, and the course could not be clearly determined in 35.0%. In total, 29.9% met the TES consensus criteria, 28.0% did not, and 42.0% had insufficient information to make a diagnostic determination. TES, in the 20th century, was described as a neurological condition, not a psychiatric disorder-and this supports the decision of the 2021 consensus group to remove primary and secondary psychiatric diagnoses from being a core diagnostic feature. Future research is needed to determine whether, or the extent to which, cognitive impairment or neurobehavioral dysregulation described as characterizing TES are associated with chronic traumatic encephalopathy neuropathological change.
Collapse
Affiliation(s)
- Grant L. Iverson
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, USA
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA
- Department of Physical Medicine and Rehabilitation, Schoen Adams Research Institute at Spaulding Rehabilitation, Charlestown, Massachusetts, USA
- Sports Concussion Program, Mass General for Children, Boston, Massachusetts, USA
- Home Base, A Red Sox Foundation and Massachusetts General Hospital Program, Charlestown, Massachusetts, USA
| | - Andrew J. Gardner
- Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia
| | - Rudolph J. Castellani
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Alicia Kissinger-Knox
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, USA
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA
- Sports Concussion Program, Mass General for Children, Boston, Massachusetts, USA
| |
Collapse
|
42
|
Liu S(S, Pickens S, Barta Z, Rice M, Dagher M, Lebens R, Nguyen TV, Cummings BJ, Cahill CM. Neuroinflammation drives sex-dependent effects on pain and negative affect in a murine model of repeated mild traumatic brain injury. Pain 2024; 165:848-865. [PMID: 37943063 PMCID: PMC10949215 DOI: 10.1097/j.pain.0000000000003084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 07/26/2023] [Accepted: 09/07/2023] [Indexed: 11/10/2023]
Abstract
ABSTRACT The Center for Disease Control and Prevention estimates that 75% of reported cases of traumatic brain injury (TBI) are mild, where chronic pain and depression are 2 of the most common symptoms. In this study, we used a murine model of repeated mild TBI to characterize the associated pain hypersensitivity and affective-like behavior and to what extent microglial reactivity contributes to these behavioral phenotypes. Male and female C57BL/6J mice underwent sham or repeated mild traumatic brain injury (rmTBI) and were tested for up to 9 weeks postinjury, where an anti-inflammatory/neuroprotective drug (minocycline) was introduced at 5 weeks postinjury in the drinking water. Repeated mild traumatic brain injury mice developed cold nociceptive hypersensitivity and negative affective states, as well as increased locomotor activity and risk-taking behavior. Minocycline reversed negative affect and pain hypersensitivities in male but not female mice. Repeated mild traumatic brain injury also produced an increase in microglial and brain-derived neurotropic factor mRNA transcripts in limbic structures known to be involved in nociception and affect, but many of these changes were sex dependent. Finally, we show that the antiepileptic drug, gabapentin, produced negative reinforcement in male rmTBI mice that was prevented by minocycline treatment, whereas rmTBI female mice showed a place aversion to gabapentin. Collectively, pain hypersensitivity, increased tonic-aversive pain components, and negative affective states were evident in both male and female rmTBI mice, but suppression of microglial reactivity was only sufficient to reverse behavioral changes in male mice. Neuroinflammation in limbic structures seems to be a contributing factor in behavioral changes resulting from rmTBI.
Collapse
Affiliation(s)
- Shiwei (Steve) Liu
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
- Department of Pharmacology, University of California Irvine, Irvine, CA, United States
| | - Sarah Pickens
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| | - Zack Barta
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| | - Myra Rice
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| | - Merel Dagher
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| | - Ryan Lebens
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| | - Theodore V. Nguyen
- Physical Medicine & Rehabilitation, Anatomy & Neurobiology, University of California Irvine, Irvine, CA, United States
| | - Brian J. Cummings
- Physical Medicine & Rehabilitation, Anatomy & Neurobiology, University of California Irvine, Irvine, CA, United States
| | - Catherine M. Cahill
- Department of Psychiatry & Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States
| |
Collapse
|
43
|
Terry DP, Jo J, Williams K, Davis P, Iverson GL, Zuckerman SL. Examining the New Consensus Criteria for Traumatic Encephalopathy Syndrome in Community-Dwelling Older Adults. J Neurotrauma 2024; 41:957-968. [PMID: 38204178 DOI: 10.1089/neu.2023.0601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2024] Open
Abstract
In 2021, an expert panel of clinician-scientists published the first consensus research diagnostic criteria for traumatic encephalopathy syndrome (TES), a clinical condition thought to be associated with chronic traumatic encephalopathy neuropathological change. This study evaluated the TES criteria in older adults and assessed associations between TES criteria and a history of repetitive head impacts. This cross-sectional, survey-based study examined the symptoms of TES, previous repetitive head impacts, and a variety of current health difficulties. To meet symptom criteria for TES, participants had to report progressive changes with memory, executive functioning, and/or neurobehavioral dysregulation. To meet the criterion for substantial exposure to repetitive head impacts via contact sports, participants reported at least 5 years of contact sport exposure (with 2+ years in high school or beyond). A sample of 507 older adults (mean age = 70.0 years, 65% women) completed the survey and 26.2% endorsed having one or more of the progressive core clinical features of TES. Those who had a significant history of contact sport exposure were not significantly more likely to meet TES criteria compared with those who did not (31.3% vs. 25.3%, p = 0.46). In a binary logistic regression predicting TES status, current depression or anxiety (odds ratio [OR] = 12.55; 95% confidence interval [CI] = 4.43-35.51), history of psychiatric disorders (OR = 2.07, 95% CI = 1.22-3.49), male sex (OR = 1.87), and sleep problems (OR = 1.71, 95% CI = 1.01-2.91) were associated with meeting TES criteria. The sport exposure criterion, age, and current pain were not significantly associated with TES status (ps > 0.05). A significant minority of participants with no history of neurotrauma endorsed symptoms consistent with TES (22.0% of men and 19.8% of women). Nearly 80% of neurotrauma naïve participants with clinically significant anxiety/depression met criteria for TES. In summary, approximately one in four older adults met the symptom criteria for TES, many of whom had no history of repetitive neurotrauma. Mental health problems and sleep issues were associated with TES, whereas having a history of repetitive head impacts in contact sports was not. These data suggest that the new consensus diagnostic criteria for TES may have low specificity and may carry a higher risk of misdiagnosing those with other physical and mental health conditions as having TES.
Collapse
Affiliation(s)
- Douglas P Terry
- Vanderbilt Sports Concussion Center, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Jacob Jo
- Vanderbilt Sports Concussion Center, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Kristen Williams
- Vanderbilt Sports Concussion Center, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Philip Davis
- Vanderbilt Sports Concussion Center, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Grant L Iverson
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusettss, USA
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital and the Schoen Adams Research Institute at Spaulding Rehabilitation, Charlestown, Massachusetts, USA
- Mass General for Children Sports Concussion Program, Waltham, Massachusetts, USA
- Home Base, A Red Sox Foundation and Massachusetts General Hospital Program, Charlestown, Massachusetts, USA
| | - Scott L Zuckerman
- Vanderbilt Sports Concussion Center, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
44
|
Koza LA, Grossberg AN, Bishop M, Prusmack C, Linseman DA. Sex-specific antioxidant biomarker depletion in patients with a history of mild traumatic brain injury. ADVANCES IN REDOX RESEARCH 2024; 10:100097. [PMID: 38562523 PMCID: PMC10976465 DOI: 10.1016/j.arres.2024.100097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Individuals with a history of mild traumatic brain injury (mTBI) are at an increased risk for neurodegenerative disease, suggesting that intrinsic neuroprotective mechanisms, such as the endogenous antioxidant reservoir, may be depleted long-term after mTBI. Here, we retrospectively analyzed symptoms and blood antioxidants in patients with a history of mTBI who presented to Resilience Code, a sports medicine clinic in Colorado. Significant decreases in alpha-tocopherol, selenium, linoleic acid, taurine, docosahexaenoic acid, and total omega-3 were measured in the total mTBI population versus controls. Male mTBI patients showed depletion of a larger array of antioxidants than females. Patients with a history of mTBI also reported significantly worsened emotional, energy, head, and cognitive symptoms, with males displaying more extensive symptomology. Multiple or chronic mTBI patients had worsened symptoms than single or acute/subchronic mTBI patients, respectively. Finally, male mTBI patients with the largest reductions in polyunsaturated fatty acids (PUFAs) displayed worse symptomology than male mTBI patients with less depletion of this antioxidant reservoir. These results demonstrate that antioxidant depletion persists in patients with a history of mTBI and these deficits are sex-specific and associated with worsened symptomology. Furthermore, supplementation with specific antioxidants, like PUFAs, may diminish symptom severity in patients suffering from chronic effects of mTBI.
Collapse
Affiliation(s)
- Lilia A. Koza
- Department of Biological Sciences and Knoebel Institute for Healthy Aging, University of Denver, Denver, CO 80208, United States
| | - Allison N. Grossberg
- Department of Biological Sciences and Knoebel Institute for Healthy Aging, University of Denver, Denver, CO 80208, United States
| | - McKensey Bishop
- Department of Biological Sciences and Knoebel Institute for Healthy Aging, University of Denver, Denver, CO 80208, United States
| | | | - Daniel A. Linseman
- Department of Biological Sciences and Knoebel Institute for Healthy Aging, University of Denver, Denver, CO 80208, United States
| |
Collapse
|
45
|
Shepherd CE, McCann H, McLean CA, Iverson GL, Gardner AJ. Chronic traumatic encephalopathy neuropathologic change in former Australian rugby players. Neuropathol Appl Neurobiol 2024; 50:e12972. [PMID: 38502287 DOI: 10.1111/nan.12972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/26/2024] [Accepted: 02/27/2024] [Indexed: 03/21/2024]
Abstract
AIMS We applied the 2021 consensus criteria for both chronic traumatic encephalopathy neuropathological change and traumatic encephalopathy syndrome in a small case series of six former elite-level Australian rugby code players. METHODS Neuropathological assessment of these cases was carried out at the Sydney and Victorian Brain Banks. Clinical data were collected via clinical interviews and health questionnaires completed by the participants and/or their next of kin, and neuropsychological testing was conducted with participants who were capable of completing this testing. RESULTS All cases exhibited progressive cognitive impairment during life. Chronic traumatic encephalopathy neuropathological change was identified in four out of the six cases. However, coexisting neuropathologies were common, with limbic-predominant age-related TDP-43 encephalopathy and ageing-related tau astrogliopathy seen in all cases, intermediate or high Alzheimer's disease neuropathological change seen in four cases and hippocampal sclerosis seen in two of the six cases. CONCLUSION The presence of multiple neuropathologies in these cases complicates clinical diagnostic efforts for traumatic encephalopathy syndrome. It will be important for further clinicopathological studies on larger groups to report all neuropathological comorbidities found in cases diagnosed with either chronic traumatic encephalopathy neuropathological change and/or traumatic encephalopathy syndrome.
Collapse
Affiliation(s)
- Claire E Shepherd
- Neuroscience Research Australia, Randwick, New South Wales, Australia
- School of Biomedical Sciences, University of New South Wales, Kensington, New South Wales, Australia
| | - Heather McCann
- Neuroscience Research Australia, Randwick, New South Wales, Australia
| | - Catriona A McLean
- Department of Anatomical Pathology, Alfred Health, Melbourne, Victoria, Australia
| | - Grant L Iverson
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, USA
- Department of Physical Medicine and Rehabilitation, Schoen Adams Research Institute at Spaulding Rehabilitation, Charlestown, Massachusetts, USA
- Home Base, A Red Sox Foundation and Massachusetts General Hospital Program, Charlestown, Massachusetts, USA
- Mass General for Children Sports Concussion Program, Boston, Massachusetts, USA
| | - Andrew J Gardner
- Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, New South Wales, Australia
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| |
Collapse
|
46
|
Barnes-Wood M, McCloskey H, Connelly S, Gilchrist MD, Annaidh AN, Theobald PS. Investigation of Head Kinematics and Brain Strain Response During Soccer Heading Using a Custom-Fit Instrumented Mouthguard. Ann Biomed Eng 2024; 52:934-945. [PMID: 38243139 PMCID: PMC10940496 DOI: 10.1007/s10439-023-03430-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Accepted: 12/21/2023] [Indexed: 01/21/2024]
Abstract
Association football, also known as soccer in some regions, is unique in encouraging its participants to intentionally use their head to gain a competitive advantage, including scoring a goal. Repetitive head impacts are now being increasingly linked to an inflated risk of developing long-term neurodegenerative disease. This study investigated the effect of heading passes from different distances, using head acceleration data and finite element modelling to estimate brain injury risk. Seven university-level participants wore a custom-fitted instrumented mouthguard to capture linear and angular acceleration-time data. They performed 10 headers within a laboratory environment, from a combination of short, medium, and long passes. Kinematic data was then used to calculate peak linear acceleration, peak angular velocity, and peak angular acceleration as well as two brain injury metrics: head injury criterion and rotational injury criterion. Six degrees of freedom acceleration-time data were also inputted into a widely accepted finite element brain model to estimate strain-response using mean peak strain and cumulative strain damage measure values. Five headers were considered to have a 25% concussion risk. Mean peak linear acceleration equalled 26 ± 7.9 g, mean peak angular velocity 7.20 ± 2.18 rad/s, mean peak angular acceleration 1730 ± 611 rad/s2, and 95th percentile mean peak strain 0.0962 ± 0.252. Some of these data were similar to brain injury metrics reported from American football, which supports the need for further investigation into soccer heading.
Collapse
Affiliation(s)
- M Barnes-Wood
- Cardiff School of Engineering, Cardiff University, The Parade, Cardiff, CF24 3AA, UK
- Charles Owen & Co, Croesfoel Industrial Park, Wrexham, LL14 4BJ, UK
| | - H McCloskey
- Cardiff School of Engineering, Cardiff University, The Parade, Cardiff, CF24 3AA, UK
- Charles Owen & Co, Croesfoel Industrial Park, Wrexham, LL14 4BJ, UK
| | - S Connelly
- Football Association of Wales (FIFA Medical Centre of Excellence), Hensol, Pontyclun, CF72 8JY, UK
| | - M D Gilchrist
- School of Mechanical and Materials Engineering, University College Dublin, Belfield, Dublin 4, Ireland
| | - A Ni Annaidh
- School of Mechanical and Materials Engineering, University College Dublin, Belfield, Dublin 4, Ireland
| | - P S Theobald
- Cardiff School of Engineering, Cardiff University, The Parade, Cardiff, CF24 3AA, UK.
| |
Collapse
|
47
|
Chen Y, Gu M, Patterson J, Zhang R, Statz JK, Reed E, Abutarboush R, Ahlers ST, Kawoos U. Temporal Alterations in Cerebrovascular Glycocalyx and Cerebral Blood Flow after Exposure to a High-Intensity Blast in Rats. Int J Mol Sci 2024; 25:3580. [PMID: 38612392 PMCID: PMC11011510 DOI: 10.3390/ijms25073580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 03/09/2024] [Accepted: 03/20/2024] [Indexed: 04/14/2024] Open
Abstract
The glycocalyx is a proteoglycan-glycoprotein structure lining the luminal surface of the vascular endothelium and is susceptible to damage due to blast overpressure (BOP) exposure. The glycocalyx is essential in maintaining the structural and functional integrity of the vasculature and regulation of cerebral blood flow (CBF). Assessment of alterations in the density of the glycocalyx; its components (heparan sulphate proteoglycan (HSPG/syndecan-2), heparan sulphate (HS), and chondroitin sulphate (CS)); CBF; and the effect of hypercapnia on CBF was conducted at 2-3 h, 1, 3, 14, and 28 days after a high-intensity (18.9 PSI/131 kPa peak pressure, 10.95 ms duration, and 70.26 PSI·ms/484.42 kPa·ms impulse) BOP exposure in rats. A significant reduction in the density of the glycocalyx was observed 2-3 h, 1-, and 3 days after the blast exposure. The glycocalyx recovered by 28 days after exposure and was associated with an increase in HS (14 and 28 days) and in HSPG/syndecan-2 and CS (28 days) in the frontal cortex. In separate experiments, we observed significant decreases in CBF and a diminished response to hypercapnia at all time points with some recovery at 3 days. Given the role of the glycocalyx in regulating physiological function of the cerebral vasculature, damage to the glycocalyx after BOP exposure may result in the onset of pathogenesis and progression of cerebrovascular dysfunction leading to neuropathology.
Collapse
Affiliation(s)
- Ye Chen
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Ming Gu
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Jacob Patterson
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- Parsons Corporation, Columbia, MD 21046, USA
| | - Ruixuan Zhang
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Jonathan K. Statz
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Eileen Reed
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- Parsons Corporation, Columbia, MD 21046, USA
| | - Rania Abutarboush
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Stephen T. Ahlers
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
| | - Usmah Kawoos
- Naval Medical Research Command, Silver Spring, MD 20910, USA; (Y.C.); (M.G.)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| |
Collapse
|
48
|
Kohl PA, Song C, Fletcher BJ, Best RL, Tchounwou C, Garcia Arceo X, Chung PJ, Miller HP, Wilson L, Choi MC, Li Y, Feinstein SC, Safinya CR. Complexes of tubulin oligomers and tau form a viscoelastic intervening network cross-bridging microtubules into bundles. Nat Commun 2024; 15:2362. [PMID: 38491006 PMCID: PMC10943092 DOI: 10.1038/s41467-024-46438-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Accepted: 02/28/2024] [Indexed: 03/18/2024] Open
Abstract
The axon-initial-segment (AIS) of mature neurons contains microtubule (MT) fascicles (linear bundles) implicated as retrograde diffusion barriers in the retention of MT-associated protein (MAP) tau inside axons. Tau dysfunction and leakage outside of the axon is associated with neurodegeneration. We report on the structure of steady-state MT bundles in varying concentrations of Mg2+ or Ca2+ divalent cations in mixtures containing αβ-tubulin, full-length tau, and GTP at 37 °C in a physiological buffer. A concentration-time kinetic phase diagram generated by synchrotron SAXS reveals a wide-spacing MT bundle phase (Bws), a transient intermediate MT bundle phase (Bint), and a tubulin ring phase. SAXS with TEM of plastic-embedded samples provides evidence of a viscoelastic intervening network (IN) of complexes of tubulin oligomers and tau stabilizing MT bundles. In this model, αβ-tubulin oligomers in the IN are crosslinked by tau's MT binding repeats, which also link αβ-tubulin oligomers to αβ-tubulin within the MT lattice. The model challenges whether the cross-bridging of MTs is attributed entirely to MAPs. Tubulin-tau complexes in the IN or bound to isolated MTs are potential sites for enzymatic modification of tau, promoting nucleation and growth of tau fibrils in tauopathies.
Collapse
Affiliation(s)
- Phillip A Kohl
- Materials Research Laboratory, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Chaeyeon Song
- Materials Department, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Amorepacific R&I Center, Yongin, 17074, Republic of Korea
| | - Bretton J Fletcher
- Materials Department, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Rebecca L Best
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Serimmune Inc., 150 Castilian Dr., Goleta, CA, 93117, USA
| | - Christine Tchounwou
- Materials Department, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Ximena Garcia Arceo
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Chemistry and Biochemistry, University of California, San Diego, San Diego, CA, 93106, USA
| | - Peter J Chung
- Materials Department, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
- Department of Physics and Astronomy, University of Southern California, Los Angeles, CA, 90089, USA
| | - Herbert P Miller
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
| | - Leslie Wilson
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Myung Chul Choi
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Daejeon, 34141, Korea
| | - Youli Li
- Materials Research Laboratory, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA.
| | - Stuart C Feinstein
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA
- Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Cyrus R Safinya
- Materials Department, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA.
- Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA.
- Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.
- Department of Physics, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA.
| |
Collapse
|
49
|
Su Y, Protas H, Luo J, Chen K, Alosco ML, Adler CH, Balcer LJ, Bernick C, Au R, Banks SJ, Barr WB, Coleman MJ, Dodick DW, Katz DI, Marek KL, McClean MD, McKee AC, Mez J, Daneshvar DH, Palmisano JN, Peskind ER, Turner RW, Wethe JV, Rabinovici G, Johnson K, Tripodis Y, Cummings JL, Shenton ME, Stern RA, Reiman EM. Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project. Alzheimers Dement 2024; 20:1827-1838. [PMID: 38134231 PMCID: PMC10984430 DOI: 10.1002/alz.13602] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 10/27/2023] [Accepted: 11/20/2023] [Indexed: 12/24/2023]
Abstract
INTRODUCTION Tau is a key pathology in chronic traumatic encephalopathy (CTE). Here, we report our findings in tau positron emission tomography (PET) measurements from the DIAGNOSE CTE Research Project. METHOD We compare flortaucipir PET measures from 104 former professional players (PRO), 58 former college football players (COL), and 56 same-age men without exposure to repetitive head impacts (RHI) or traumatic brain injury (unexposed [UE]); characterize their associations with RHI exposure; and compare players who did or did not meet diagnostic criteria for traumatic encephalopathy syndrome (TES). RESULTS Significantly elevated flortaucipir uptake was observed in former football players (PRO+COL) in prespecified regions (p < 0.05). Association between regional flortaucipir uptake and estimated cumulative head impact exposure was only observed in the superior frontal region in former players over 60 years old. Flortaucipir PET was not able to differentiate TES groups. DISCUSSION Additional studies are needed to further understand tau pathology in CTE and other individuals with a history of RHI.
Collapse
Affiliation(s)
- Yi Su
- Banner Alzheimer's Institute and Arizona Alzheimer's ConsortiumPhoenixArizonaUSA
| | - Hillary Protas
- Banner Alzheimer's Institute and Arizona Alzheimer's ConsortiumPhoenixArizonaUSA
| | - Ji Luo
- Banner Alzheimer's Institute and Arizona Alzheimer's ConsortiumPhoenixArizonaUSA
| | - Kewei Chen
- Banner Alzheimer's Institute and Arizona Alzheimer's ConsortiumPhoenixArizonaUSA
| | - Michael L. Alosco
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Charles H. Adler
- Department of NeurologyMayo Clinic College of Medicine, Mayo Clinic ArizonaScottsdaleArizonaUSA
| | - Laura J. Balcer
- Departments of NeurologyNYU Grossman School of MedicineNew YorkNew YorkUSA
- Department of Population Health and OphthalmologyNYU Grossman School of MedicineNew YorkNew YorkUSA
| | - Charles Bernick
- Cleveland Clinic Lou Ruvo Center for Brain HealthLas VegasNevadaUSA
- Department of NeurologyUniversity of WashingtonSeattleWashingtonUSA
| | - Rhoda Au
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Framingham Heart StudyFraminghamMassachusettsUSA
- Slone Epidemiology Center; Departments of Anatomy & Neurobiology, Neurology, and MedicineDepartment of EpidemiologyBoston University Chobanian & Avedisian School of Medicine; Boston University School of Public HealthBostonMassachusettsUSA
| | - Sarah J. Banks
- Departments of Neuroscience and PsychiatryUniversity of CaliforniaSan DiegoCaliforniaUSA
| | - William B. Barr
- Departments of NeurologyNYU Grossman School of MedicineNew YorkNew YorkUSA
| | - Michael J. Coleman
- Departments of Psychiatry and RadiologyPsychiatry Neuroimaging LaboratoryBrigham and Women's Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - David W. Dodick
- Department of NeurologyMayo Clinic College of Medicine, Mayo Clinic ArizonaScottsdaleArizonaUSA
| | - Douglas I. Katz
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Encompass Health Braintree Rehabilitation HospitalBraintreeMassachusettsUSA
| | - Kenneth L. Marek
- Institute for Neurodegenerative Disorders, Invicro, LLCNew HavenConnecticutUSA
| | - Michael D. McClean
- Department of Environmental HealthBoston University School of Public HealthBostonMassachusettsUSA
| | - Ann C. McKee
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- VA Boston Healthcare SystemBostonMassachusettsUSA
| | - Jesse Mez
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Framingham Heart StudyFraminghamMassachusettsUSA
| | - Daniel H. Daneshvar
- Department of Physical Medicine & RehabilitationMassachusetts General Hospital, Spaulding Rehabilitation Hospital, Harvard Medical SchoolCharlestownMassachusettsUSA
| | - Joseph N. Palmisano
- Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public HealthBostonMassachusettsUSA
| | - Elaine R. Peskind
- Department of Psychiatry and Behavioral SciencesVA Northwest Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System; University of Washington School of MedicineSeattleWashingtonUSA
| | - Robert W. Turner
- Department of Clinical Research & LeadershipThe George Washington University School of Medicine & Health SciencesWashingtonDistrict of ColumbiaUSA
| | - Jennifer V. Wethe
- Department of Psychiatry and PsychologyMayo Clinic School of Medicine, Mayo Clinic ArizonaScottsdaleArizonaUSA
| | - Gil Rabinovici
- Department of NeurologyUniversity of California San FranciscoSan FranciscoCaliforniaUSA
| | - Keith Johnson
- Gordon Center for Medical Imaging, Mass General Research Institute, Harvard Medical SchoolBostonMassachusettsUSA
| | - Yorghos Tripodis
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
| | - Jeffrey L. Cummings
- Department of Brain HealthChambers‐Grundy Center for Transformative NeuroscienceSchool of Integrated Health Sciences, University of Nevada Las VegasLas VegasNevadaUSA
| | - Martha E. Shenton
- Departments of Psychiatry and RadiologyPsychiatry Neuroimaging LaboratoryBrigham and Women's Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Robert A. Stern
- Department of NeurologyBoston University Alzheimer's Disease Research CenterBoston University CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Eric M. Reiman
- Banner Alzheimer's Institute and Arizona Alzheimer's ConsortiumPhoenixArizonaUSA
- University of Arizona, Arizona State University, Translational Genomics Research InstitutePhoenixArizonaUSA
| | | |
Collapse
|
50
|
Kim JH, Im JG, Park SH. Measurement of changes in cerebrospinal fluid pulsation after traumatic brain injury using echo-planar imaging-based functional MRI. NMR IN BIOMEDICINE 2024; 37:e5061. [PMID: 37839870 DOI: 10.1002/nbm.5061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 09/19/2023] [Accepted: 09/21/2023] [Indexed: 10/17/2023]
Abstract
Traumatic brain injury (TBI) is a major public health concern worldwide, with a high incidence and a significant impact on morbidity and mortality. The alteration of cerebrospinal fluid (CSF) dynamics after TBI is a well-known phenomenon; however, the underlying mechanisms and their implications for cognitive function are not fully understood. In this study, we propose a new approach to studying the alteration of CSF dynamics in TBI patients. Our approach involves using conventional echo-planar imaging-based functional MRI with no additional scan, allowing for simultaneous assessment of functional CSF dynamics and blood oxygen level-dependent-based functional brain activities. We utilized two previously suggested indices of (i) CSFpulse, and (ii) correlation between global brain activity and CSF inflow. Using CSFpulse, we demonstrated a significant decrease in CSF pulsation following TBI (p < 0.05), which was consistent with previous studies. Furthermore, we confirmed that the decrease in CSF pulsation was most prominent in the early months after TBI, which could be explained by ependymal ciliary loss, intracranial pressure increment, or aquaporin-4 dysregulation. We also observed a decreasing trend in the correlation between global brain activity and CSF inflow in TBI patients (p < 0.05). Our findings suggest that the decreased CSF pulsation after TBI could lead to the accumulation of toxic substances in the brain and an adverse effect on brain function. Further longitudinal studies with larger sample sizes, TBI biomarker data, and various demographic information are needed to investigate the association between cognitive decline and CSF dynamics after TBI. Overall, this study sheds light on the potential role of altered CSF dynamics in TBI-induced neurologic symptoms and may contribute to the development of novel therapeutic interventions.
Collapse
Affiliation(s)
- Jun-Hee Kim
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea
| | - Jae-Geun Im
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea
| | - Sung-Hong Park
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea
| |
Collapse
|